: The AMEDEO Literature Guide

Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription

Articles published in Eur Urol
Retrieve available abstracts of 402 articles:
HTML format

Single Articles

October 2026

GULATI R, Etzioni R
Re: Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9 yr Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial.
Eur Urol. 2026 Oct 1:S0302-2838(26)02408-5. doi: 10.1016/j.eururo.2026.
PubMed

September 2026

BRYANT RJ, Sharma AD
Re: Alexander Light, Max Peters, Archana Gopalakrishnan, et al. Oncological Outcomes Following Focal HIFU and Cryotherapy for Treatment of Nonmetastatic Prostate Cancer in the United Kingdom: An Updated Analysis of 3477 Patients from the Prospective H
Eur Urol. 2026 Sep 30:S0302-2838(26)02419-X. doi: 10.1016/j.eururo.2026.
PubMed

FASULO V, Lughezzani G, Lazzeri M, Buffi NM, et al
Re: Prostate Cancer.
Eur Urol. 2026 Sep 30:S0302-2838(26)02050-6. doi: 10.1016/j.eururo.2026.
PubMed

LOMBARDO R, Santioni M, De Nunzio C
Re: Bi-Ming He, Keqin Zhang, Zhien Zhou, et al. Cognitive Versus Software-based Fusion-targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION). Eur Urol 2026. In press.
Eur Urol. 2026 Sep 30:S0302-2838(26)02411-5. doi: 10.1016/j.eururo.2026.
PubMed

PASQUIER D, Flippot R, Fizazi K
Stereotactic Body Radiation Therapy in Oligometastatic Castration-resistant Prostate Cancer: Time to Move from Signals to Phase 3 Trial Evidence.
Eur Urol. 2026 Sep 30:S0302-2838(26)02369-9. doi: 10.1016/j.eururo.2026.
PubMed

VITI A, Cucchiara V, Gandaglia G, Briganti A, et al
Re: [(177)Lu]Lu-PSMA-617 in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-naive/sensitive Prostate Cancer (PSMAddition): A Phase 3 Randomised, Controlled Trial.
Eur Urol. 2026 Sep 30:S0302-2838(26)02371-7. doi: 10.1016/j.eururo.2026.
PubMed

BRATT O, Lantz A, Godtman RA
Re: Agne Krilaviciute, Nikolaus Becker, Sigrid V. Carlsson, et al. Confirmation of Prostate-specific Antigen (PSA) Values Improves Prostate Cancer Screening in Early Middle-aged Men - Data from the PROBASE Trial. Eur Urol. In press. https://doi.org/10
Eur Urol. 2026 Sep 25:S0302-2838(26)02373-0. doi: 10.1016/j.eururo.2026.
PubMed

BERGMAN DT, Nagar H, McClure TD
Re: Alexander Light, Max Peters, Archana Gopalakrishnan, et al. Oncological Outcomes Following Focal HIFU and Cryotherapy for Treatment of Nonmetastatic Prostate Cancer in the United Kingdom: An Updated Analysis of 3477 Patients from the Prospective H
Eur Urol. 2026 Sep 23:S0302-2838(26)02375-4. doi: 10.1016/j.eururo.2026.
PubMed

LONGONI M, Gandaglia G, Montorsi F
Re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. In pre
Eur Urol. 2026 Sep 16:S0302-2838(25)04745-1. doi: 10.1016/j.eururo.2025.
PubMed

FROEHNER M
Re: Derya Tilki, Roderick C.N.van den Bergh, Erik Briers, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.e
Eur Urol. 2026 Sep 16:S0302-2838(26)02374-2. doi: 10.1016/j.eururo.2026.
PubMed

TAHA T, Longoria O, de Bono J
Challenges of Using Circulating Tumour DNA: Insights from Advanced Prostate Cancer.
Eur Urol. 2026 Sep 15:S0302-2838(26)02302-X. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

VAN AS N, Tree A, Ost P
Re: Light A, Peters M, Gopalakrishnan A, et al. Oncological Outcomes Following Focal HIFU and Cryotherapy for Treatment of Nonmetastatic Prostate Cancer in the United Kingdom: An Updated Analysis of 3477 Patients from the Prospective HEAT and ICE Regi
Eur Urol. 2026 Sep 10:S0302-2838(26)02356-0. doi: 10.1016/j.eururo.2026.
PubMed

NGUYEN DD, Najafabadi BT, Rosella LC, Dahm P, et al
Reply to T. Takahashi's Letter to the Editor re: Re: Nguyen DD, Tadayon Najafabadi B, Lin L, et al. Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Met
Eur Urol. 2026 Sep 9:S0302-2838(26)02274-8. doi: 10.1016/j.eururo.2026.
PubMed

GRAY S, Dutey-Magni P, Jones C, Murphy LR, et al
Impact of Treatment Intensification with Abiraterone on Fracture-related Hospitalisation in Newly Diagnosed Prostate Cancer: A Secondary Analysis of Two Randomised Phase 3 Trials Within the STAMPEDE Trial Platform.
Eur Urol. 2026 Sep 8:S0302-2838(26)02355-9. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

CORNFORD P, van den Bergh RCN, Briers E, Chiu P, et al
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.
Eur Urol. 2026 Sep 1:S0302-2838(26)02114-7. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

FOSSATI N, Montorsi F, Stenzl A, Penson D, et al
Optimizing Quality-of-life Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer.
Eur Urol. 2026 Sep 1:S0302-2838(26)02344-4. doi: 10.1016/j.eururo.2026.
PubMed

ZAURITO P, Gandaglia G, Montorsi F
Re: Robert M. Meier, Nima Aghdam, Alan C. Beckman, et al. 10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.029.
Eur Urol. 2026 Sep 1:S0302-2838(26)02348-1. doi: 10.1016/j.eururo.2026.
PubMed

CHERNYSHEVA D, Di Bello F, Avesani G, Baboudjian M, et al
ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy.
Eur Urol. 2026;90:212-224.
PubMed Abstract available

August 2026

LIGHT A, Peters M, Ahmed HU, Shah TT, et al
Reply to Marcio C. Moschovas, Ugo Falagario, Francesco Pellegrino, et al's Letter to the Editor re: Alexander Light, Max Peters, Manit Arya, et al's Salvage Focal Therapy vs Radical Prostatectomy for Localized Radiorecurrent Prostate Cancer. JAMA Onco
Eur Urol. 2026 Aug 18:S0302-2838(26)02321-3. doi: 10.1016/j.eururo.2026.
PubMed

RANNIKKO AS, Kilpelainen TP, Auvinen A
Why Look Further When the Solution Is in Front of You - or Is It? The Value of Confirmatory PSA in Prostate Cancer Screening.
Eur Urol. 2026 Aug 12:S0302-2838(26)02316-X. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

SAAD F, Shore N, Vjaters E, Olmos D, et al
Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial.
Eur Urol. 2026 Aug 12:S0302-2838(26)02313-4. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

QUARTA L, Zaurito P, Viti A, Cosenza A, et al
PSMA Radio-guided Surgery to Identify Lymph Node Metastases in Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Phase 2 Prospective Study.
Eur Urol. 2026 Aug 11:S0302-2838(26)02314-6. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

GUO C, Figueiredo I, Gurel B, Neeb A, et al
Corrigendum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [European Urology 83 (2023) 224-238.
Eur Urol. 2026 Aug 7:S0302-2838(26)02318-3. doi: 10.1016/j.eururo.2026.
PubMed

FROEHNER M
Re: Armstrong AJ, Petrylak DP, Shore ND, et al. ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients. Eur Urol 2026. In press. http://dx.doi.org/10.1016/j.eururo.2025.12.02
Eur Urol. 2026 Aug 7:S0302-2838(26)02161-5. doi: 10.1016/j.eururo.2026.
PubMed

GRISAY G, Turco F, Patrikidou A, Gallardo E, et al
EORTC 2238 DE-ESCALATE: Revisiting Intermittent Maximal Androgen Blockade in Metastatic Hormone-sensitive Prostate Cancer.
Eur Urol. 2026 Aug 5:S0302-2838(26)02286-4. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

LUCA S, Ferrando L, Porpiglia F
Re: Emanuele Messina, Antonella Borrelli, Alessandro Sciarra, et al. Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA). Eur Urol 2025;89:246-57.
Eur Urol. 2026 Aug 4:S0302-2838(26)02218-9. doi: 10.1016/j.eururo.2026.
PubMed

July 2026

KISHAN AU, Sun Y, Parker CC, Sargos P, et al
Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis.
Eur Urol. 2026 Jul 28:S0302-2838(26)02270-0. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

SANTIAGO I, Rivas JG
Re: EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer.
Eur Urol. 2026 Jul 25:S0302-2838(26)02285-2. doi: 10.1016/j.eururo.2026.
PubMed

BLANCHARD P, Sighinolfi C, Terlizzi M, Rocco B, et al
Five-Year Patient-Reported Outcomes After SBRT for Prostate Cancer: A Benchmark for Radiotherapy, but How Far Across Modalities?
Eur Urol. 2026 Jul 24:S0302-2838(26)02300-6. doi: 10.1016/j.eururo.2026.
PubMed

MORTEZAVI A, van der Hulle T, van den Bergh R
What Comes After Matters: The Importance of Postprogression Care in Patients with Metastatic Hormone-sensitive Prostate Cancer.
Eur Urol. 2026 Jul 23:S0302-2838(26)02258-X. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

ULERI A, Baboudjian M, Lughezzani G, Ploussard G, et al
Re: James P. Buteau, Daniel Moon, Michael T. Fahey, et al. Effect of [(68)Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings on Multiparametric MRI (PRIMARY2): A Multicenter,
Eur Urol. 2026 Jul 23:S0302-2838(26)02269-4. doi: 10.1016/j.eururo.2026.
PubMed

KIM JS, Chang AR, Kim JH
Re: Robert M. Meier, Nima Aghdam, Alan C. Beckman et al. 10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial. Eur Urol In press. http://dx.doi.org/10.1016/j.eururo.2026.04.029.
Eur Urol. 2026 Jul 23:S0302-2838(26)02276-1. doi: 10.1016/j.eururo.2026.
PubMed

NGUYEN DD, Najafabadi BT, Lin L, Kwong JCC, et al
Reply to J.H. Kim and Y.S. Shin's Letter to the Editor re: Re: Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled T
Eur Urol. 2026 Jul 21:S0302-2838(26)02272-4. doi: 10.1016/j.eururo.2026.
PubMed

AL-KHANATY A, Delgado C, Berg E, Sandhu K, et al
RE: Perioperative Apalutamide in High-Risk Localized Prostate Cancer.
Eur Urol. 2026 Jul 16:S0302-2838(26)02260-8. doi: 10.1016/j.eururo.2026.
PubMed

MAY M, Burger M, Brookman-May SD
Re: Prostate-specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer.
Eur Urol. 2026 Jul 16:S0302-2838(26)02261-X. doi: 10.1016/j.eururo.2026.
PubMed

URSO L, Giannarini G, Girometti R, Crestani A, et al
Re: Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings in Multiparametric MRI (PRIMARY2): A Multicentre, Non-inferiority, Phase 3, Randomised Controlled Trial.
Eur Urol. 2026 Jul 16:S0302-2838(26)02268-2. doi: 10.1016/j.eururo.2026.
PubMed

BELLIVEAU C, Kishan AU, Calais J, Plouznikoff N, et al
Re: [177Lu]-PSMA-617-PSMA-617 in Oligometastatic Hormone Sensitive Prostate Cancer (BULLSEYE): An Open-label, Randomised, Phase 2 Study.
Eur Urol. 2026 Jul 15:S0302-2838(26)02264-5. doi: 10.1016/j.eururo.2026.
PubMed

O'CALLAGHAN ME, Selth L, Wittert G
Re: Testosterone Treatment in Prostate Cancer Survivors with Hypogonadism: A Randomized Clinical Trial.
Eur Urol. 2026 Jul 15:S0302-2838(26)02262-1. doi: 10.1016/j.eururo.2026.
PubMed

TILKI D, van den Bergh RCN, Briers E, Chiu P, et al
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
Eur Urol. 2026 Jul 15:S0302-2838(26)02116-0. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

MESSINA E, Sciarra A, La Torre G, Panebianco V, et al
Re: De Luca et al. Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA). Eur Urol 2026;89:246-57.
Eur Urol. 2026 Jul 14:S0302-2838(26)02234-7. doi: 10.1016/j.eururo.2026.
PubMed

HEIDEGGER I
Re: Luka Cavka, Subhiksha Nandakumar, Qingqing Wu, et al. IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.014.
Eur Urol. 2026 Jul 13:S0302-2838(26)02257-8. doi: 10.1016/j.eururo.2026.
PubMed

KRILAVICIUTE A, Becker N, Carlsson SV, Kaaks R, et al
Confirmation of Prostate-specific Antigen (PSA) Values Improves Prostate Cancer Screening in Early Middle-Aged Men - Data from the PROBASE Trial.
Eur Urol. 2026 Jul 13:S0302-2838(26)02239-6. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

SHIN YS, Kim JH
Re: David-Dan Nguyen, Borna Tadayon Najafabadi, Lauren Lin, et al. Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controll
Eur Urol. 2026 Jul 11:S0302-2838(26)02255-4. doi: 10.1016/j.eururo.2026.
PubMed

LIGHT A, Peters M, Gopalakrishnan A, Mayor N, et al
Oncological Outcomes Following Focal HIFU and Cryotherapy for Treatment of Nonmetastatic Prostate Cancer in the United Kingdom: An Updated Analysis of 3477 Patients from the Prospective HEAT and ICE Registries.
Eur Urol. 2026 Jul 10:S0302-2838(26)02169-X. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

HE BM, Zhang K, Zhou Z, Chen X, et al
Cognitive Versus Software-based Fusion Targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION).
Eur Urol. 2026 Jul 10:S0302-2838(26)02243-8. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

SHORE ND, Freedland SJ
Reply to Francesco Barletta, Chiara Mercinelli, Francesco Montorsi, et al. re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.019.
Eur Urol. 2026 Jul 10:S0302-2838(26)02156-1. doi: 10.1016/j.eururo.2026.
PubMed

STABILE A, Montorsi F
Focal Therapy for Localized Prostate Cancer: Maturing Evidence, Evolving Questions.
Eur Urol. 2026 Jul 7:S0302-2838(26)02236-0. doi: 10.1016/j.eururo.2026.
PubMed

FANTI S, Turco F, Tombal B, Walz J, et al
Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.
Eur Urol. 2026 Jul 3:S0302-2838(26)02230-X. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

June 2026

VITI A, Scuderi S, Cucchiara V, Gandaglia G, et al
Re: Hormone Therapy Use and Duration with Postoperative Radiotherapy for Recurrent Prostate Cancer: an Individual Patient Data Meta-analysis.
Eur Urol. 2026 Jun 29:S0302-2838(26)02221-9. doi: 10.1016/j.eururo.2026.
PubMed

TAKAHASHI T
Re: Nguyen DD, Tadayon Najafabadi B, Lin L, et al. Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur U
Eur Urol. 2026 Jun 29:S0302-2838(26)02238-4. doi: 10.1016/j.eururo.2026.
PubMed

MA H, Zhang L
Re: Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men with Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE).
Eur Urol. 2026 Jun 23:S0302-2838(26)02215-3. doi: 10.1016/j.eururo.2026.
PubMed

DAVIS ID
Re: Transdermal Estradiol Patches in Locally Advanced Prostate Cancer.
Eur Urol. 2026 Jun 17:S0302-2838(26)02177-9. doi: 10.1016/j.eururo.2026.
PubMed

FRANCINI E
Re: Final Overall Survival Results from EORTC 1333/PEACE-3 Trial of Enzalutamide plus Radium-223 in Metastatic Castration-resistant Prostate Cancer.
Eur Urol. 2026 Jun 16:S0302-2838(26)02175-5. doi: 10.1016/j.eururo.2026.
PubMed

YUSUF S, Azam A, Sood I, Al-Sattar H, et al
Re: Stereotactic Body Radiation Therapy for Oligoprogressive Disease in Androgen-suppressed Prostate Cancer: Primary Endpoint Analysis of the TRAP Trial.
Eur Urol. 2026 Jun 16:S0302-2838(26)02185-8. doi: 10.1016/j.eururo.2026.
PubMed

SOORIAKUMARAN P, Bryant RJ, Hamdy FC
Radical Prostatectomy in Low-volume Metastatic Prostate Cancer? The Need for New Evidence.
Eur Urol. 2026 Jun 12:S0302-2838(26)02213-X. doi: 10.1016/j.eururo.2026.
PubMed

COVAS MOSCHOVAS M, Falagario U, Pellegrino F, Wiklund P, et al
Reply to Alexander Light, Max Peters, Manit Arya, et al's Salvage Focal Therapy vs Radical Prostatectomy for Localized Radiorecurrent Prostate Cancer. JAMA Oncol 2026;12:364-73. https://doi.org/10.1001/jamaoncol.2025.6448.
Eur Urol. 2026 Jun 11:S0302-2838(26)02210-4. doi: 10.1016/j.eururo.2026.
PubMed

FROEHNER M
Re: Brian F. Chapin, Marc Smaldone, Amado J. Zurita, et al. A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer. Eur Urol. In Press.
Eur Urol. 2026 Jun 9:S0302-2838(26)02188-3. doi: 10.1016/j.eururo.2026.
PubMed

KISHAN AU, Francolini G, Murphy DG, Eapen RS, et al
A Multidisciplinary Approach to Prevention and Treatment of Late Genitourinary Adverse Events After Radiotherapy for Prostate Cancer.
Eur Urol. 2026 Jun 6:S0302-2838(26)02170-6. doi: 10.1016/j.eururo.2026.
PubMed

DING G, Wang J, Wu J
Re: Khan S, Papa N, Kneebone A, et al. Prospective Comparison of (64)Copper [(64)Cu]SAR-bisPSMA vs (68)Gallium[(68)Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial). Eur Urol. In press. ht
Eur Urol. 2026 Jun 3:S0302-2838(26)02164-0. doi: 10.1016/j.eururo.2026.
PubMed

May 2026

AL-MONAJJED R, Albers P, van Poppel H, Bratt O, et al
From Evidence to Implementation: How Should We Screen for Prostate Cancer in the Modern Era?: Editorial to: Nguyen DD, Tadayon B, Lin L, et al. Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-spe
Eur Urol. 2026 May 20:S0302-2838(26)02158-5. doi: 10.1016/j.eururo.2026.
PubMed

DE LAERE B, Mortezavi A, Eklund M, Gronberg H, et al
Letter to the Editor: Advanced and Metastatic Prostate Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment, and Follow-up.
Eur Urol. 2026 May 14:S0302-2838(26)02148-2. doi: 10.1016/j.eururo.2026.
PubMed

CAVKA L, Nandakumar S, Wu Q, Mehta NJ, et al
IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer.
Eur Urol. 2026 May 13:S0302-2838(26)02049-X. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

MEIER RM, Aghdam N, Beckman AC, Woodhouse SA, et al
10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial.
Eur Urol. 2026 May 8:S0302-2838(26)02153-6. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

NGUYEN DD, Tadayon Najafabadi B, Lin L, Kwong JCC, et al
Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Eur Urol. 2026 May 5:S0302-2838(26)02107-X. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

April 2026

LI T, Nguyen DD, Khondker A, Kwong JCC, et al
Re: Personalizing Prostate Cancer Education for Patients Using an EHR-Integrated LLM Agent.
Eur Urol. 2026 Apr 28:S0302-2838(26)02110-X. doi: 10.1016/j.eururo.2026.
PubMed

NG CPY, Light A, Ahmed H, Shah T, et al
Reply to Ashwini Kadam, Ankit Misra and Gagan Prakash's Letter to the Editor Re: Chase Peng Yun Ng, Alexander Light, Sai Kalpitha Eragamreddy, et al. Five-year Outcomes for Men after Negative Magnetic Resonance Imaging (MRI) or Negative Biopsy in the
Eur Urol. 2026 Apr 27:S0302-2838(26)02061-0. doi: 10.1016/j.eururo.2026.
PubMed

GARNICK MB, Herrmann K
Considerations for Earlier Use of Radiopharmaceutical Therapy in Prostate Cancer.
Eur Urol. 2026 Apr 15:S0302-2838(26)02036-1. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

KADAM A, Misra A, Prakash G
Re: Chase Peng Yun Ng, Alexander Light, Sai Kalpitha Eragamreddy, et al. Five-year Outcomes for Men after Negative Magnetic Resonance Imaging (MRI) or Negative Biopsy in the RAPID MRI-directed Prostate Cancer Diagnostic Pathway. Eur Urol. In press. ht
Eur Urol. 2026 Apr 8:S0302-2838(26)02062-2. doi: 10.1016/j.eururo.2026.
PubMed

March 2026

MONTIRONI R, Giannarini G, Cimadamore A, Lopez-Beltran A, et al
Re: European Study of Prostate Cancer Screening - 23-Year Follow-up.
Eur Urol. 2026 Mar 30:S0302-2838(26)02048-8. doi: 10.1016/j.eururo.2026.
PubMed

KHAN S, Papa N, Kneebone A, Eade T, et al
Prospective Comparison of (64)Copper [(64)Cu]SAR-bisPSMA vs (68)Gallium[(68)Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial).
Eur Urol. 2026 Mar 27:S0302-2838(26)02035-X. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

CHAPIN BF, Smaldone M, Zurita AJ, Wang J, et al
A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer.
Eur Urol. 2026 Mar 11:S0302-2838(26)02002-6. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

PORPIGLIA F, Checcucci E, Volpi G, Stura I, et al
Artificial Intelligence 3D Augmented Reality-guided Robotic Prostatectomy Versus Cognitive MRI Intervention: Results of the Prospective Randomized RIDERS Trial.
Eur Urol. 2026;89:233-243.
PubMed Abstract available

MAYOR N, Light A, Silvanto A, Haider A, et al
IP8-FLUORESCE: A Prospective Paired Cohort Study Evaluating the Diagnostic Accuracy of Fluorescence Confocal Microscopy for Real-time Assessment of Surgical Margins in Radical Prostatectomy.
Eur Urol. 2026;89:223-232.
PubMed Abstract available

HERRMANN K, Walz J, MacLennan S, Briganti A, et al
SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis.
Eur Urol. 2026;89:260-274.
PubMed Abstract available

February 2026

BRATT O, Egevad L
Re: Active Monitoring, Surgery, and Radiotherapy for Cribriform-positive and Cribriform-negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial.
Eur Urol. 2026 Feb 23:S0302-2838(26)01992-5. doi: 10.1016/j.eururo.2026.
PubMed

BANCROFT EK, Page EC, McHugh J, Thomas S, et al
Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study.
Eur Urol. 2026 Feb 18:S0302-2838(26)00057-6. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

STRIEDER DE OLIVEIRA G, Altmayer S, Torri GB, Prediger JE, et al
Diagnostic Performance of Biparametric versus Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis: An Updated Systematic Review and Meta-analysis.
Eur Urol. 2026 Feb 16:S0302-2838(26)00058-8. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

VITI A, Scuderi S, Briganti A, Gandaglia G, et al
Re: Optimal Duration of Androgen Deprivation Therapy with Definitive Radiotherapy for Localized Prostate Cancer. A Meta-analysis.
Eur Urol. 2026 Feb 11:S0302-2838(26)00029-1. doi: 10.1016/j.eururo.2026.
PubMed

BARLETTA F, Mercinelli C, Montorsi F, Gandaglia G, et al
Re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Eur Urol. 2026 Feb 9:S0302-2838(26)00026-6. doi: 10.1016/j.eururo.2026.
PubMed

ARMSTRONG AJ, Petrylak DP, Shore ND, Szmulewitz RZ, et al
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients.
Eur Urol. 2026 Feb 2:S0302-2838(25)04876-6. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

January 2026

PINI C, Gelardi F, Sollini M, Chiti A, et al
Targeting Prostatic Acid Phosphatase in Prostate Cancer: Roadmap on How To Venture Above and Beyond Prostate-specific Membrane Antigen with ACP3 Theranostics.
Eur Urol. 2026 Jan 20:S0302-2838(26)00020-5. doi: 10.1016/j.eururo.2026.
PubMed

BENESOVA-SCHAFER M, Haberkorn U, Babich JW
The Discovery of Prostate-specific Membrane Antigen Ligands: The Long Road to Changes in Clinical Practice for Prostate Cancer.
Eur Urol. 2026 Jan 14:S0302-2838(26)00003-5. doi: 10.1016/j.eururo.2026.
PubMed Abstract available

GHADJAR P, Hayoz S, Zwahlen DR, Holscher T, et al
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial.
Eur Urol. 2026 Jan 5:S0302-2838(25)04875-4. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

RATNAKUMARAN R, Brand DH, Sasitharan A, Mohajer J, et al
Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B Study.
Eur Urol. 2026;89:71-79.
PubMed Abstract available

KISHAN AU, Juarez Casillas JE, Sargos P, Kalbasi TR, et al
Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial.
Eur Urol. 2026;89:12-17.
PubMed Abstract available

MARVASO G, Francolini G, Achard V, Gomez-Iturriaga A, et al
Should We Embark on "EMBARK"? Reassessing the Role of Radiotherapy and Androgen Receptor Pathway Inhibitors in the Era of Next-generation Imaging.
Eur Urol. 2026;89:5-7.
PubMed Abstract available

December 2025

FALKENBACH F, Beyer B, Graefen M
Reply to Salvatore Cozzi and Thomas Zilli's, and Alexander Ho and Sean Sachdev's Letters to the Editor re: Markus Graefen, Fabian Falkenbach, Tobias Maurer, et al. Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men Wi
Eur Urol. 2025 Dec 27:S0302-2838(25)04868-7. doi: 10.1016/j.eururo.2025.
PubMed

BARATA PC, Grier AL
Re: Final Overall Survival and Safety Analyses of the Phase III PSMAfore Trial of [(177)Lu]Lu-PSMA-617 Versus Change of Androgen Receptor Pathway Inhibitor in Taxane-Naive Patients with Metastatic Castration-Resistant Prostate Cancer.
Eur Urol. 2025 Dec 19:S0302-2838(25)04858-4. doi: 10.1016/j.eururo.2025.
PubMed

CARLSSON SV, Krilaviciute A, Al-Monajjed R, Seibold P, et al
Risk-adapted Prostate Cancer Screening Achieves Mammography-like Benefits: Evidence and Implications for Europe.
Eur Urol. 2025 Dec 18:S0302-2838(25)04855-9. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

VICKERS AJ, Fine S
Evaluating Tumor Quantification in Place of Proportions in Prostate Cancer: Principles of the ProQuant Group.
Eur Urol. 2025 Dec 18:S0302-2838(25)04835-3. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

BACKHAUS P, Cazzamalli S, Oehler S, Buther F, et al
Translational and First-in-Human Positron Emission Tomography Targeting Prostatic Acid Phosphatase in Prostate Cancer Using the Ligand [(68)Ga]Ga-OncoACP3-DOTA.
Eur Urol. 2025 Dec 17:S0302-2838(25)04848-1. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

JANI AB, Dhere VR, Goyal S, Schreibmann E, et al
[(18)F]-Fluciclovine or [(68)Ga]-PSMA-11 Molecular Imaging To Guide Dose Escalation of Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer: The EMPIRE-2 Trial.
Eur Urol. 2025 Dec 17:S0302-2838(25)04857-2. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

MESSINA E, Borrelli A, Sciarra A, Laschena L, et al
Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA).
Eur Urol. 2025 Dec 17:S0302-2838(25)04847-X. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

NGUYEN DD, Kulkarni GS, Guyatt GH
Re: European Study of Prostate Cancer Screening - 23-Year Follow-up.
Eur Urol. 2025 Dec 16:S0302-2838(25)04862-6. doi: 10.1016/j.eururo.2025.
PubMed

MCKENZIE J, Azad AA
Re: Niraparib and Abiraterone Acetate plus Prednisone for HRR-deficient Metastatic Castration-sensitive Prostate Cancer: A Randomized Phase 3 Trial.
Eur Urol. 2025 Dec 16:S0302-2838(25)04861-4. doi: 10.1016/j.eururo.2025.
PubMed

PEDRANI M, Gillessen S, Briers E, Blanchard P, et al
Beyond Menopause: Ending the Inequality-Why Men with Prostate Cancer Still Lack Therapies for Hot Flushes.
Eur Urol. 2025 Dec 13:S0302-2838(25)04856-0. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

TILKI D, Chen MH, D'Amico AV
Re: Alexander B.C.D. Ng, Aqua Asif, Ridhi Agarwal, et al. Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial. JAMA 2025;334:1170-9.
Eur Urol. 2025 Dec 12:S0302-2838(25)04853-5. doi: 10.1016/j.eururo.2025.
PubMed

GANDAGLIA G, Briganti A, Catto JW, Cornford P, et al
Re: Rebecca Voelker. What Is Prostate Cancer? JAMA. In press. https://doi.org/10.1001/jama.2025.10177.
Eur Urol. 2025 Dec 12:S0302-2838(25)04849-3. doi: 10.1016/j.eururo.2025.09.4181.
PubMed

COZZI S, Zilli T
Re: Markus Graefen, Fabian Falkenbach, Tobias Maurer, et al. Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial. Eur Urol. In press. https://
Eur Urol. 2025 Dec 12:S0302-2838(25)04850-X. doi: 10.1016/j.eururo.2025.
PubMed

PATTOU M, Peyrottes A, Long-Depaquit T, Tokarski E, et al
Re: Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis. The PRIME Diagnostic Clinical Trial.
Eur Urol. 2025 Dec 10:S0302-2838(25)04841-9. doi: 10.1016/j.eururo.2025.
PubMed

HO A, Sachdev S
Re: Markus Graefen, Fabian Falkenbach, Tobias Maurer, et al. Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial. Eur Urol. In press. https://
Eur Urol. 2025 Dec 8:S0302-2838(25)04843-2. doi: 10.1016/j.eururo.2025.
PubMed

BRIERS E
SPARC: The Importance for Patients with Prostate Cancer.
Eur Urol. 2025 Dec 6:S0302-2838(25)04837-7. doi: 10.1016/j.eururo.2025.
PubMed

November 2025

BERTOLO R, Antonelli A
Re: Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial.
Eur Urol. 2025 Nov 14:S0302-2838(25)04793-1. doi: 10.1016/j.eururo.2025.
PubMed

NG CPY, Light A, Eragamreddy SK, Boaz RJ, et al
Five-year Outcomes for Men after Negative Magnetic Resonance Imaging (MRI) or Negative Biopsy in the RAPID MRI-directed Prostate Cancer Diagnostic Pathway.
Eur Urol. 2025 Nov 7:S0302-2838(25)04778-5. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

CHEN F, Sheng X, Wang A, Xu Y, et al
Integrating Pathogenic Variants, Polygenic Risk Score, and Family History for Prostate Cancer Risk Estimation in Men of African Ancestry.
Eur Urol. 2025 Nov 5:S0302-2838(25)04720-7. doi: 10.1016/j.eururo.2025.09.4161.
PubMed Abstract available

RIAZ IB, Ahmed Naqvi SA, Faisal KS, He H, et al
Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis.
Eur Urol. 2025 Nov 4:S0302-2838(25)00509-3. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

October 2025

CORNFORD P
Reply to Andrew J. Vickers' Letter to the Editor re: Matthew J. Roberts, Giorgio Gandaglia, Daniela E. Oprea-Lager, et al. Pelvic Lymph Node Dissection in Prostate Cancer: Evidence and Implications. Eur Urol 2025;87:619-21.
Eur Urol. 2025 Oct 30:S0302-2838(25)04723-2. doi: 10.1016/j.eururo.2025.09.4163.
PubMed

KARPINSKI MJ, Hoberuck S, Fendler WP, Civan C, et al
Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry.
Eur Urol. 2025 Oct 29:S0302-2838(25)04773-6. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

FETTKE H, Kostos L, Docanto M, Bukczynska P, et al
Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [(177)Lu]Lu-PSMA-617.
Eur Urol. 2025 Oct 29:S0302-2838(25)00501-9. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

DEMOGEOT N, Supiot S, Sargos P
Reply to Mattia Longoni, Giorgio Gandaglia, and Francesco Montorsi's Letter to the Editor re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Local
Eur Urol. 2025 Oct 23:S0302-2838(25)04741-4. doi: 10.1016/j.eururo.2025.09.4176.
PubMed

DEMOGEOT N, Supiot S, Sargos P
Reply to Federico Iori, Emanuele Ali, and Cinzia Iotti's Letter to the Editor re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostat
Eur Urol. 2025 Oct 23:S0302-2838(25)04740-2. doi: 10.1016/j.eururo.2025.09.4175.
PubMed

CHA E, Lin Z, Lu J, Oliveira LD, et al
Histopathology-based Artificial Intelligence Algorithms for the Prediction of Prostate Cancer Metastasis After Radical Prostatectomy.
Eur Urol. 2025 Oct 23:S0302-2838(25)00495-6. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

PILATZ A, Cornford P, Bonkat G, Kranz J, et al
Transperineal Prostate Biopsy Without Antibiotic Prophylaxis: The New Gold Standard? Recommendations from the European Association of Urology Guidelines on Prostate Cancer and Urological Infections.
Eur Urol. 2025 Oct 23:S0302-2838(25)04737-2. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

FREEDLAND SJ, Shore N
Reply to Xianghu Meng, Yibo Hua, and Rijin Song's Letter to the Editor re: Stephen J. Freedland, John P. Mulhall, Martin Gleave, et al. Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc
Eur Urol. 2025 Oct 22:S0302-2838(25)04744-X. doi: 10.1016/j.eururo.2025.09.4179.
PubMed

SCHELTEMA MJV, Stricker PD
Prospective Multicentre Validation of Focal Irreversible Electroporation as an Attractive Treatment Option for Localised Intermediate-risk Prostate Cancer.
Eur Urol. 2025 Oct 16:S0302-2838(25)04738-4. doi: 10.1016/j.eururo.2025.
PubMed

VIGNESWARAN HT, Palsdottir T, Micoli C, Tilki D, et al
Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial.
Eur Urol. 2025 Oct 16:S0302-2838(25)04735-9. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

RIAZ IB, Cheng L, Montironi R
Histopathology-only Artificial Intelligence for Prostate Cancer: Towards Accessible Risk Stratification.
Eur Urol. 2025 Oct 10:S0302-2838(25)04722-0. doi: 10.1016/j.eururo.2025.09.4164.
PubMed

WANG Z, Li X, Zhao X, Yang Y, et al
Re: Emmeli Palmstedt, Marianne Mansson, Jonas Hugosson, Rebecka Arnsrud Godtman. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GOTEBORG-1 Trial. Eur Urol. In press. https:/
Eur Urol. 2025 Oct 9:S0302-2838(25)04728-1. doi: 10.1016/j.eururo.2025.
PubMed

IORI F, Ali E, Iotti C
Re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. In pre
Eur Urol. 2025 Oct 9:S0302-2838(25)04726-8. doi: 10.1016/j.eururo.2025.09.4167.
PubMed

MENG X, Hua Y, Song R
Re: Stephen J. Freedland, John P. Mulhall, Martin Gleave, et al. Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study. Eur Urol 20
Eur Urol. 2025 Oct 9:S0302-2838(25)04727-X. doi: 10.1016/j.eururo.2025.
PubMed

ENGLMAN C, Giganti F, Moore CM
Reply to Francesco Montorsi, Paolo Zauirto, and Giorgio Gandaglia's Letter to the Editor re: Cameron Englman, Busola Adebusoye, Davide Maffei, et al. Magnetic Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results
Eur Urol. 2025 Oct 7:S0302-2838(25)04703-7. doi: 10.1016/j.eururo.2025.09.4153.
PubMed

KHALIL N, Maiolino G, Barret E
Re: Rui M. Bernardino, Theodorus van der Kwast, Neil E. Fleshner. Intraductal Carcinoma and Cribriform Pattern in Prostate Cancer: Challenges and Emerging Perspectives. Eur Urol 2025;88:123-5.
Eur Urol. 2025 Oct 6:S0302-2838(25)04709-8. doi: 10.1016/j.eururo.2025.09.4159.
PubMed

HOLMBERG L, Adami HO, Bill-Axelson A
Reply to Yafei Wang, Qianting Lu, and Xin Zhao's Letter to the Editor re: Lars Holmberg, Hans Garmo, Sven-Olov Andersson, et al. Time Dependence of Outcomes in the SPCG-4 Randomized Trial Comparing Radical Prostatectomy and Watchful Waiting in Early P
Eur Urol. 2025 Oct 6:S0302-2838(25)04701-3. doi: 10.1016/j.eururo.2025.09.4151.
PubMed

VICKERS AJ, Touijer K
Re: Matthew J. Roberts, Giorgio Gandaglia, Daniela E. Oprea-Lager, et al. Pelvic Lymph Node Dissection in Prostate Cancer: Evidence and Implications. Eur Urol 2025;87:619-21.
Eur Urol. 2025 Oct 6:S0302-2838(25)04694-9. doi: 10.1016/j.eururo.2025.
PubMed

LIN PH, Burwell AD, Freedland SJ
Reply to Nastasiia Artamonova and Isabel Heidegger's Letter to the Editor re: Pao-Hwa Lin, Alanna D. Burwell, Edward L. Giovannucci, et al. Dietary Patterns in Prostate Cancer Prevention and Management: A Systematic Review of Prospective Cohort Studie
Eur Urol. 2025 Oct 4:S0302-2838(25)04706-2. doi: 10.1016/j.eururo.2025.09.4156.
PubMed

GRAEFEN M, Falkenbach F, Maurer T, Budaus L, et al
Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial.
Eur Urol. 2025 Oct 3:S0302-2838(25)04687-1. doi: 10.1016/j.eururo.2025.09.4144.
PubMed Abstract available

September 2025

LIU H, Sun F, Wu J
Re: Arvin K. George, Ranko Miocinovic, Amit R. Patel, et al. Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial. Eur Urol. In press. https://doi.org/10.1016/j.e
Eur Urol. 2025 Sep 27:S0302-2838(25)04691-3. doi: 10.1016/j.eururo.2025.
PubMed

CONTEDUCA V, Bruno G, Landriscina M
Reconciling Clinical and Molecular Heterogeneity in Metastatic Castration-resistant Prostate Cancer: The Promise of Integrated Prognostic Models.
Eur Urol. 2025 Sep 27:S0302-2838(25)04676-7. doi: 10.1016/j.eururo.2025.09.4140.
PubMed

ARTAMONOVA N, Heidegger I
Re: Pao-Hwa Lin, Alanna D. Burwell, Edward L. Giovannucci, et al. Dietary Patterns in Prostate Cancer Prevention and Management: A Systematic Review of Prospective Cohort Studies and Randomized Clinical Trials. Eur Urol. In press. https://doi.org/10.1
Eur Urol. 2025 Sep 27:S0302-2838(25)04697-4. doi: 10.1016/j.eururo.2025.09.4147.
PubMed

WANG Y, Lu Q, Zhao X
Re: Lars Holmberg, Hans Garmo, Sven-Olov Andersson, et al. Time Dependence of Outcomes in the SPCG-4 Randomized Trial Comparing Radical Prostatectomy and Watchful Waiting in Early Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2
Eur Urol. 2025 Sep 27:S0302-2838(25)04696-2. doi: 10.1016/j.eururo.2025.
PubMed

BERNARDINO RM, van der Kwast T, Fleshner NE
Reply to Nour Khalil, Guiseppe Maiolino, and Eric Barret's Letter to the Editor re: Rui M. Bernardino, Theodorus van der Kwast, Neil E. Fleshner. Intraductal Carcinoma and Cribriform Pattern in Prostate Cancer: Challenges and Emerging Perspectives. Eu
Eur Urol. 2025 Sep 27:S0302-2838(25)04689-5. doi: 10.1016/j.eururo.2025.09.4146.
PubMed

STRAUSS AS, Cleves A, Dahm P
Re: Elio Mazzone, Alice Thomson, David C. Chen, et al. The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer Aft
Eur Urol. 2025 Sep 26:S0302-2838(25)04651-2. doi: 10.1016/j.eururo.2025.09.4131.
PubMed

MONTORSI F, Zaurito P, Gandaglia G
Re: Cameron Englman, Busola Adebusoye, Davide Maffei, et al. Magnetic Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Study. Eur Urol 2025;88:167-75.
Eur Urol. 2025 Sep 26:S0302-2838(25)04685-8. doi: 10.1016/j.eururo.2025.
PubMed

FISHER DJ, Burdett S, Vale CL
Reply to Shenglong Li and Cuicui Wang's Letter to the Editor re: Sarah Burdett, David J. Fisher, Jayne F. Tierney, et al. Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Sy
Eur Urol. 2025 Sep 25:S0302-2838(25)04653-6. doi: 10.1016/j.eururo.2025.
PubMed

MONTIRONI R, Cimadamore A, Lopez-Beltran A, Cheng L, et al
Re: Lucia L. Rijstenberg, Hridya Harikumara, Esther I. Verhoef, et al. Identification of Intraductal-to-Invasive Spatial Transitions in Prostate Cancer: Proposal for a New Unifying Model on Intraductal Carcinogenesis. Histopathology 2025;86:1091-100.
Eur Urol. 2025 Sep 25:S0302-2838(25)04656-1. doi: 10.1016/j.eururo.2025.
PubMed

MISZCZYK M, Sanchez-Salas R, Emberton M, Shariat SF, et al
Re: Karolina Menne Guricova, Cedric Draulans, Floris J. Pos, et al. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients with Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial. J Clin Oncol. In press. https:/
Eur Urol. 2025 Sep 24:S0302-2838(25)04650-0. doi: 10.1016/j.eururo.2025.09.4133.
PubMed

PALMSTEDT E, Hugosson J, Arnsrud Godtman R
Reply to Kevin B. Ginsburg, Ava Zamani, and Tudor Borza's Letter to the Editor re: Emmeli Palmstedt, Marianne Mansson, Jonas Hugosson, Rebecka Arnsrud Godtman. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extende
Eur Urol. 2025 Sep 24:S0302-2838(25)04644-5. doi: 10.1016/j.eururo.2025.09.4130.
PubMed

GINSBURG KB, Zamani A, Borza T
Re: Emmeli Palmstedt, Marianne Mansson, Jonas Hugosson, Rebecka Arnsrud Godtman. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GOTEBORG-1 Trial. Eur Urol. In press. https:/
Eur Urol. 2025 Sep 24:S0302-2838(25)04647-0. doi: 10.1016/j.eururo.2025.
PubMed

STABILE A, Montorsi F
Re: Arvin K. George, Ranko Miocinovic, Amit R. Patel, et al. Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial. Eur Urol. In press. https://doi.org/10.1016/j.e
Eur Urol. 2025 Sep 23:S0302-2838(25)04641-X. doi: 10.1016/j.eururo.2025.09.4128.
PubMed

ENGLMAN C, Adebusoye B, Mallett S, Giganti F, et al
Reply to Yuan Du, Dan Liu, and Zhihui Guan's Letter to the Editor re: Cameron Englman, Busola Adebusoye, Davide Maffei, et al. Magnetic Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Stu
Eur Urol. 2025 Sep 18:S0302-2838(25)00500-7. doi: 10.1016/j.eururo.2025.
PubMed

DU Y, Liu D, Guan Z
Re: Cameron Englman, Busola Adebusoye, Davide Maffei, et al. Magnetic Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.03.0
Eur Urol. 2025 Sep 9:S0302-2838(25)00478-6. doi: 10.1016/j.eururo.2025.
PubMed

LI J, Zhang Y, Hu H
Re: Metformin for Patients with Metastatic Prostate Cancer Starting Androgen Deprivation Therapy: A Randomised Phase 3 Trial of the STAMPEDE Platform Protocol.
Eur Urol. 2025 Sep 8:S0302-2838(25)00483-X. doi: 10.1016/j.eururo.2025.
PubMed

LI S, Wang C
Re: Sarah Burdett, David J Fisher, Jayne F. Tierney, et al. Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data. Eur Urol.
Eur Urol. 2025 Sep 6:S0302-2838(25)00480-4. doi: 10.1016/j.eururo.2025.
PubMed

August 2025

LIN PH, Burwell AD, Giovannucci EL, Loeb S, et al
Dietary Patterns in Prostate Cancer Prevention and Management: A Systematic Review of Prospective Cohort Studies and Randomized Clinical Trials.
Eur Urol. 2025 Aug 19:S0302-2838(25)00433-6. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

SCUDERI S, Gandaglia G, Briganti A, Montorsi F, et al
Re: Prostate Cancer: A Review.
Eur Urol. 2025 Aug 19:S0302-2838(25)00437-3. doi: 10.1016/j.eururo.2025.
PubMed

DEMOGEOT N, Sargos P, Salleron J, Guerif S, et al
Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial.
Eur Urol. 2025 Aug 14:S0302-2838(25)00436-1. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

SANTIAGO I, Rivas JG
Re: EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer.
Eur Urol. 2025 Aug 13:S0302-2838(25)00440-3. doi: 10.1016/j.eururo.2025.
PubMed

FAHRNER M, Zamboglou C, Spohn SKB, Oerther B, et al
Advancing Radioproteomics: Integration of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging with Localized Proteomic Profiling in Prostate Cancer.
Eur Urol. 2025 Aug 11:S0302-2838(25)00393-8. doi: 10.1016/j.eururo.2025.
PubMed

MONTORSI F, Barletta F, Gandaglia G, Briganti A, et al
Re: Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial.
Eur Urol. 2025 Aug 11:S0302-2838(25)00400-2. doi: 10.1016/j.eururo.2025.
PubMed

HALABI S, Guo S, Luo B, Yu C, et al
Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer.
Eur Urol. 2025 Aug 6:S0302-2838(25)00407-5. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

July 2025

SHERRY AD, Siddiqui BA, Haymaker C, Fellman BM, et al
Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial.
Eur Urol. 2025 Jul 31:S0302-2838(25)00396-3. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

HOLMBERG L, Garmo H, Andersson SO, Andren O, et al
Time Dependence of Outcomes in the SPCG-4 Randomized Trial Comparing Radical Prostatectomy and Watchful Waiting in Early Prostate Cancer.
Eur Urol. 2025 Jul 30:S0302-2838(25)00390-2. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

THOMAS C, Hadaschik B
Re: Salvage Metastasis-directed Therapy Versus Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases (PEACE V-STORM): A Phase 2, Open-label, Randomised Controlled Trial.
Eur Urol. 2025 Jul 30:S0302-2838(25)00398-7. doi: 10.1016/j.eururo.2025.
PubMed

TURKBEY B, Schoots IG, Haider MA
Reply to Masatomo Kaneko, Vasileios Magoulianitis, Vinay Duddalwar, et al's Letter to the Editor re: Baris Turkbey, Henkjan Huisman, Andriy Fedorov, et al. Requirements for AI Development and Reporting for MRI Prostate Cancer Detection in Biopsy-naive
Eur Urol. 2025 Jul 28:S0302-2838(25)00395-1. doi: 10.1016/j.eururo.2025.
PubMed

ALBERS P
Re: Local Anaesthetic Transperineal Biopsy Versus Transrectal Prostate Biopsy in Prostate Cancer Detection (TRANSLATE): A Multicentre, Randomised, Controlled Trial.
Eur Urol. 2025 Jul 25:S0302-2838(25)00401-4. doi: 10.1016/j.eururo.2025.
PubMed

VAN DEN BERGH RCN, van der Poel HG, van Leeuwen PJ, van Soest RJ, et al
Re: Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial.
Eur Urol. 2025 Jul 25:S0302-2838(25)00399-9. doi: 10.1016/j.eururo.2025.
PubMed

CIMADAMORE A, Boixareu C, Sharp A, Beltran H, et al
Novel Therapeutic Strategies for Metastatic Prostate Cancer Care.
Eur Urol. 2025 Jul 19:S0302-2838(25)00357-4. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

GEORGE AK, Miocinovic R, Patel AR, Lomas DJ, et al
Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial.
Eur Urol. 2025 Jul 19:S0302-2838(25)00346-X. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

COVAS MOSCHOVAS M, Saikali S, Sandri M, Bravi C, et al
Outcomes of Salvage Robotic-assisted Radical Prostatectomy: High-volume Multicentric Data from the European Association of Urology Robotic Urology Section Scientific Working Group.
Eur Urol. 2025;88:103-113.
PubMed Abstract available

June 2025

CARLSSON SV
Rethinking Early Detection: Magnetic Resonance Imaging Strategies for Smarter Prostate Cancer Screening.
Eur Urol. 2025 Jun 25:S0302-2838(25)00356-2. doi: 10.1016/j.eururo.2025.
PubMed

PALMSTEDT E, Mansson M, Hugosson J, Arnsrud Godtman R, et al
Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GOTEBORG-1 Trial.
Eur Urol. 2025 Jun 25:S0302-2838(25)00358-6. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

BURDETT S, Fisher DJ, Tierney JF, Cook AD, et al
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data.
Eur Urol. 2025 Jun 25:S0302-2838(25)00291-X. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

KARPINSKI MJ, Hadaschik BA, Fendler WP
Reply to Zhengbo Pan, Run Shi, and Zhaokai Zhou's Letter to the Editor - Re: Madeleine J. Karpinski, Kambiz Rahbar, Martin Bogemann, et al. Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate
Eur Urol. 2025 Jun 23:S0302-2838(25)00349-5. doi: 10.1016/j.eururo.2025.
PubMed

DAVIS ID
If the Treatment for Metastatic Hormone-sensitive Prostate Cancer Stops Working, What Next?
Eur Urol. 2025 Jun 21:S0302-2838(25)00354-9. doi: 10.1016/j.eururo.2025.
PubMed

PAN Z, Shi R, Zhou Z
Re: Madeleine J. Karpinski, Kambiz Rahbar, Martin Bogemann, et al. Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an
Eur Urol. 2025 Jun 20:S0302-2838(25)00352-5. doi: 10.1016/j.eururo.2025.
PubMed

KANEKO M, Magoulianitis V, Duddalwar V, Aron M, et al
Re: Baris Turkbey, Henkjan Huisman, Andriy Fedorov, et al. Requirements for AI Development and Reporting for MRI Prostate Cancer Detection in Biopsy-Naive Men: PI-RADS Steering Committee, Version 1.0. Radiology 2025;315:e24014.
Eur Urol. 2025 Jun 20:S0302-2838(25)00351-3. doi: 10.1016/j.eururo.2025.
PubMed

GRIMM MO, Smith M, Hussain M, Saad F, et al
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial.
Eur Urol. 2025 Jun 20:S0302-2838(25)00340-9. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

SCHOOTS IG, Ahmed HU, Albers P, Asbach P, et al
Magnetic Resonance Imaging-based Biopsy Strategies in Prostate Cancer Screening: A Systematic Review.
Eur Urol. 2025 Jun 12:S0302-2838(25)00341-0. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

COOPERBERG MR, Grummet J, Eggener SE
Re: Rajal B. Shah, Gladell P. Paner, Liang Cheng, et al. Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: Call for a Multidisciplinary Approach. Eur Urol. In press. htt
Eur Urol. 2025 Jun 12:S0302-2838(25)00331-8. doi: 10.1016/j.eururo.2025.
PubMed

KRISTIANSEN G, Paner GP, Shah RB
Reply to Matthew R. Cooperberg, Jeremy Grummet, and Scott E. Eggener's Letter to the Editor re: Rajal B. Shah, Gladell P. Paner, Liang Cheng, et al. Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defin
Eur Urol. 2025 Jun 7:S0302-2838(25)00330-6. doi: 10.1016/j.eururo.2025.
PubMed

SHERRYN S, Baskoro B, Sun J
Re: Veeru Kasivisvanathan, Vinson Wai-Shun Chan, Keiran D. Clement, et al. An Individual Patient Data Meta-analysis of Randomised Trials Comparing Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound Guided Biopsy in the Det
Eur Urol. 2025 Jun 7:S0302-2838(25)00332-X. doi: 10.1016/j.eururo.2025.
PubMed

ALBERTSEN P
Re: Assessment of a Polygenic Risk Score in Screening for Prostate Cancer.
Eur Urol. 2025 Jun 6:S0302-2838(25)00328-8. doi: 10.1016/j.eururo.2025.
PubMed

AL-MONAJJED R, Boschheidgen M, Lakes J, Krilaviciute A, et al
Prostate Cancer Detection in Younger Men: A Comparative Analysis of Systematic and Magnetic Resonance Imaging-targeted Biopsy in the PROBASE Trial.
Eur Urol. 2025 Jun 2:S0302-2838(25)00298-2. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

JOSEFSSON A, Carlsson SV, Lilja H, Godtman R, et al
Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Andreas Josefsson, Marianne Mansson, Kimia Kohestani, et al. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in th
Eur Urol. 2025;87:e112-e113.
PubMed

DE BONO JS, He M, Shi Z, Nowicka M, et al
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial.
Eur Urol. 2025;87:672-682.
PubMed Abstract available

May 2025

ENGLMAN C, Adebusoye B, Maffei D, Stavrinides V, et al
Magnetic Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Study.
Eur Urol. 2025 May 27:S0302-2838(25)00192-7. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

LI KD, Carlisle MN, Jarosek S, Patel HV, et al
Evolving Risk of Urinary Adverse Events Across Localized Prostate Cancer Treatments: A Propensity-weighted Analysis of Surveillance, Epidemiology and End Results-Medicare Data.
Eur Urol. 2025 May 22:S0302-2838(25)00293-3. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

LEE W, Chung JY, Baidoo KE, Nambiar D, et al
Glypican-3 as a Radiotheranostic Target for Neuroendocrine Prostate Cancer.
Eur Urol. 2025 May 21:S0302-2838(25)00284-2. doi: 10.1016/j.eururo.2025.
PubMed

MAZZONE E, Thomson A, Chen DC, Cannoletta D, et al
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-a
Eur Urol. 2025 May 19:S0302-2838(25)00285-4. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

COOPERBERG MR
Prostate Cancer Active Surveillance Without Biopsy? Not Quite Yet, but Watch This Space.
Eur Urol. 2025 May 19:S0302-2838(25)00286-6. doi: 10.1016/j.eururo.2025.
PubMed

HENNES D, Al-Khanaty A, Chen DC, Dineen E, et al
Re: Local Anaesthetic Transperineal Biopsy Versus Transrectal Prostate Biopsy in Prostate Cancer Detection (TRANSLATE): A Multicentre, Randomised, Controlled Trial.
Eur Urol. 2025 May 16:S0302-2838(25)00288-X. doi: 10.1016/j.eururo.2025.
PubMed

CHU G, Li Z, Niu H
Re: Assessment of a Polygenic Risk Score in Screening for Prostate Cancer.
Eur Urol. 2025 May 16:S0302-2838(25)00289-1. doi: 10.1016/j.eururo.2025.
PubMed

CHEN DC, Al-Khanaty A, Hennes D, Perera ML, et al
Re: Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial.
Eur Urol. 2025 May 9:S0302-2838(25)00262-3. doi: 10.1016/j.eururo.2025.
PubMed

LI Y, Xie N, Chen R, Lee AR, et al
Corrigendum to "RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression" [Eur. Urol. 76(2) (2019) 157-166].
Eur Urol. 2025 May 7:S0302-2838(25)00261-1. doi: 10.1016/j.eururo.2025.
PubMed

ULERI A, Baboudjian M, Ploussard G
Re: Richard J. Bryant, Ioana R. Marian, Roxanne Williams, et al. Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial. Lancet Oncol. In press. h
Eur Urol. 2025 May 3:S0302-2838(25)00259-3. doi: 10.1016/j.eururo.2025.
PubMed

KARPINSKI MJ, Rahbar K, Bogemann M, Nikoukar LR, et al
Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study.
Eur Urol. 2025 May 2:S0302-2838(25)00249-0. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

LAO Y, Guan X, Bai Y, Dong Z, et al
Re: Aram Lyu, Zenghua Fan, Matthew Clark, et al. Evolution of Myeloid-mediated Immunotherapy Resistance in Prostate Cancer. Nature 2025;637:1207-17.
Eur Urol. 2025 May 2:S0302-2838(25)00258-1. doi: 10.1016/j.eururo.2025.
PubMed

PLOUSSARD G, Coloby P, Chevallier T, Occean BV, et al
Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial.
Eur Urol. 2025;87:526-533.
PubMed Abstract available

April 2025

NG AB, Giganti F, Kasivisvanathan V
Artificial Intelligence in Prostate Cancer Diagnosis on Magnetic Resonance Imaging: Time for a New PARADIGM.
Eur Urol. 2025 Apr 30:S0302-2838(25)00252-0. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

GOMEZ RIVAS J, Moreno Sierra J
Re: Darolutamide in Combination with Androgen-deprivation Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer from the Phase III ARANOTE Trial.
Eur Urol. 2025 Apr 23:S0302-2838(25)00208-8. doi: 10.1016/j.eururo.2025.
PubMed

GOMEZ RIVAS J, Moreno Sierra J
Re: [(177)Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ENZA-p): An Open-label, Multicentre, Randomised, Phase 2 Trial.
Eur Urol. 2025 Apr 22:S0302-2838(25)00207-6. doi: 10.1016/j.eururo.2025.
PubMed

VICKERS A, Touijer K
Re: Philip Cornford, Roderick C.N. van den Bergh, Erik Briers, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2024;86:148-63.
Eur Urol. 2025 Apr 12:S0302-2838(25)00200-3. doi: 10.1016/j.eururo.2025.
PubMed

ARMSTRONG AJ, Sartor O, de Bono J, Chi K, et al
Corrigendum to "Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial" [Eur. Urol. 86 (2024) 552-562
Eur Urol. 2025 Apr 8:S0302-2838(25)00179-4. doi: 10.1016/j.eururo.2025.
PubMed

CHEN S, Xu H, Chen X, Shen Q, et al
First-in-human Study of a Dual-modality Prostate-specific Membrane Antigen-targeted Probe for Preoperative Positron Emission Tomography/Computed Tomography Imaging and Intraoperative Fluorescence Imaging in Prostate Cancer.
Eur Urol. 2025 Apr 8:S0302-2838(25)00182-4. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

ROBERTS MJ, Gandaglia G, Oprea-Lager DE, Stranne J, et al
Pelvic Lymph Node Dissection in Prostate Cancer: Evidence and Implications.
Eur Urol. 2025 Apr 7:S0302-2838(25)00154-X. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

March 2025

MAZZONE E, Cannoletta D, Quarta L, Chen DC, et al
A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment.
Eur Urol. 2025 Mar 27:S0302-2838(25)00155-1. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

MONTORSI F, Gandaglia G, Barletta F, Briganti A, et al
Re: Andreas Josefsson, Marianne Mansson, Kimia Kohestani, et al. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GOTEBORG-2 Prostate Cancer Screening Trial. Eur Urol 2024;86:223-9.
Eur Urol. 2025 Mar 26:S0302-2838(25)00124-1. doi: 10.1016/j.eururo.2025.
PubMed

SHAH RB, Paner GP, Cheng L, De Marzo AM, et al
Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: Call for a Multidisciplinary Approach.
Eur Urol. 2025 Mar 17:S0302-2838(25)00150-2. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

HAGE CHEHADE C, Ozay ZI, Ostrowski M, Mercinelli C, et al
T-cell Engagers in Prostate Cancer.
Eur Urol. 2025 Mar 11:S0302-2838(25)00070-3. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

DEVOS G, Giesen A, Joniau S
When Less Is More: The Challenges of Defining Residual Disease Following Neoadjuvant Hormonal Therapy in Prostate Cancer.
Eur Urol. 2025 Mar 10:S0302-2838(25)00146-0. doi: 10.1016/j.eururo.2025.
PubMed

TAHA T, Koster KL, de Bono JS
T-Cell Engagers in Prostate Cancer: Promise, Challenges, and the Road Ahead.
Eur Urol. 2025 Mar 5:S0302-2838(25)00147-2. doi: 10.1016/j.eururo.2025.
PubMed

GILLESSEN S, Tombal B, Turco F, Choudhury A, et al
Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis.
Eur Urol. 2025;87:285-288.
PubMed Abstract available

February 2025

FREEDLAND SJ, Mulhall JP, Gleave M, Giorgi U, et al
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study.
Eur Urol. 2025 Feb 26:S0302-2838(25)00094-6. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

AZAD AA, Kostos L, Agarwal N, Attard G, et al
Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer.
Eur Urol. 2025 Feb 12:S0302-2838(25)00023-5. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

RAVI P, Kwak L, Acosta AM, Rastogi S, et al
Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer.
Eur Urol. 2025 Feb 6:S0302-2838(25)00027-2. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

CASTRO E, Lorente D, Olmos D
PARP Inhibitors and Prostate Cancer: The Struggle To Separate the Grain from the Chaff.
Eur Urol. 2025 Feb 3:S0302-2838(25)00024-7. doi: 10.1016/j.eururo.2025.
PubMed

MORGAN TM, Daignault-Newton S, Spratt DE, Dunn RL, et al
Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial.
Eur Urol. 2025;87:228-237.
PubMed Abstract available

January 2025

BERNARDINO RM, van der Kwast T, Fleshner NE
Intraductal Carcinoma and Cribriform Pattern in Prostate Cancer: Challenges and Emerging Perspectives.
Eur Urol. 2025 Jan 30:S0302-2838(25)00025-9. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

NAQVI SAA, Riaz IB, Bibi A, Khan MA, et al
Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis.
Eur Urol. 2025 Jan 22:S0302-2838(24)02760-X. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

MURTHY V, Marvaso G, Jereczek-Fossa BA, Thoma SA, et al
The Co-IMPACT Consortium: Integrating Prostate-specific Membrane Antigen Positron Emission Tomography and Radiotherapy in Prostate Cancer Care.
Eur Urol. 2025 Jan 20:S0302-2838(25)00008-9. doi: 10.1016/j.eururo.2025.
PubMed Abstract available

LONGONI M, Briganti A, Gandaglia G, Montorsi F, et al
Re: Metastatic Hormone-sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.
Eur Urol. 2025 Jan 10:S0302-2838(25)00001-6. doi: 10.1016/j.eururo.2025.
PubMed

LEENEN RCA, Roobol MJ, Beyer K
Reply to Jonas Hugosson. Population-based Screening for Prostate Cancer: Is It Time? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.11.003.
Eur Urol. 2025 Jan 4:S0302-2838(24)02767-2. doi: 10.1016/j.eururo.2024.
PubMed

EL-TAJI O, Clarke NW
Balancing Efficacy and Cardiotoxicity in Prostate Cancer Therapy: A Call for Precision in Treatment Strategies.
Eur Urol. 2025;87:27-28.
PubMed

ONG WL, Romero T, Roy S, Nikitas J, et al
Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium.
Eur Urol. 2025;87:49-57.
PubMed Abstract available

December 2024

STRANNE J, Henry A, Oprea-Lager DE
Use of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Nodal Staging in Prostate Cancer and Tailoring of Treatment: A Continuing Conundrum.
Eur Urol. 2024 Dec 18:S0302-2838(24)02745-3. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

TISSEVERASINGHE S, Tolba M, Saad F, Fizazi K, et al
Optimal Treatment Strategies for Hormone-sensitive Metastatic Prostate Cancer: Does Local Radiotherapy Play a Role in High-volume Disease?
Eur Urol. 2024 Dec 17:S0302-2838(24)02748-9. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

DIAS AB, Moore CM, Renard-Penna R, Giganti F, et al
Biparametric Versus Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Choice or a Fine Balance?
Eur Urol. 2024 Dec 16:S0302-2838(24)02740-4. doi: 10.1016/j.eururo.2024.
PubMed

DAVIS JW
Multiparametric Magnetic Resonance Imaging with Targeted-only Biopsy-A New Standard for Guidelines on Prostate Cancer Detection?
Eur Urol. 2024 Dec 11:S0302-2838(24)02717-9. doi: 10.1016/j.eururo.2024.
PubMed

SCHAFER EJ, Laversanne M, Sung H, Soerjomataram I, et al
Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update.
Eur Urol. 2024 Dec 5:S0302-2838(24)02707-6. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

November 2024

MADEC FX, Mesnard B, Dariane C
Re: Prevalence and Factors Associated with Prostate Cancer Among Transgender Women.
Eur Urol. 2024 Nov 21:S0302-2838(24)02704-0. doi: 10.1016/j.eururo.2024.
PubMed

COOPERBERG MR
Re: Artificial Intelligence and Radiologists in Prostate Cancer Detection on MRI (PI-CAI): An International, Paired, Non-inferiority, Confirmatory Study.
Eur Urol. 2024 Nov 21:S0302-2838(24)02700-3. doi: 10.1016/j.eururo.2024.
PubMed

HUGOSSON J
Population-based Screening for Prostate Cancer: Is it Time?
Eur Urol. 2024 Nov 20:S0302-2838(24)02696-4. doi: 10.1016/j.eururo.2024.
PubMed

DAHM P, Wilt TJ
Re: Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer.
Eur Urol. 2024 Nov 15:S0302-2838(24)02687-3. doi: 10.1016/j.eururo.2024.
PubMed

KISHAN AU, Lamb JM, Wilhalme H, Casado M, et al
Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial.
Eur Urol. 2024 Nov 12:S0302-2838(24)02688-5. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

GHADJAR P, Zips D
Re: Duration of Androgen Deprivation Therapy with Postoperative Radiotherapy for Prostate Cancer: A Comparison of Long-course Versus Short-course Androgen Deprivation Therapy in the RADICALS-HD Randomised Trial.
Eur Urol. 2024 Nov 12:S0302-2838(24)02691-5. doi: 10.1016/j.eururo.2024.
PubMed

ARMSTRONG WR, Kishan AU, Booker KM, Grogan TR, et al
Corrigendum to "Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)" [
Eur Urol. 2024 Nov 8:S0302-2838(24)02684-8. doi: 10.1016/j.eururo.2024.
PubMed

PARKER CC, Clarke NW, Cook AD, Petersen PM, et al
Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047).
Eur Urol. 2024;86:422-430.
PubMed Abstract available

LANE BR, Dess RT, Borza T
More Than Words: Defining Adjuvant, Consolidative, and Salvage Treatment after Radical Prostatectomy.
Eur Urol. 2024;86:385-387.
PubMed Abstract available

October 2024

OH WK, Agarwal N, Bryce A, Barata P, et al
What's in a Name? Why Words Matter in Advanced Prostate Cancer.
Eur Urol. 2024 Oct 28:S0302-2838(24)02680-0. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

TOUIJER KA, Vertosick EA, Sjoberg DD, Liso N, et al
Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection.
Eur Urol. 2024 Oct 28:S0302-2838(24)02647-2. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

TWILT JJ, Saha A, Bosma JS, van Ginneken B, et al
Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study.
Eur Urol. 2024 Oct 21:S0302-2838(24)02640-X. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

VANDERWEELE DJ, Hussain M
Management Decisions for Metastatic Castration-resistant Prostate Cancer in 2024.
Eur Urol. 2024 Oct 19:S0302-2838(24)02646-0. doi: 10.1016/j.eururo.2024.
PubMed

EVANGELISTA L, Cecchi L, Zucali PA
Advancing Prostate Cancer Care: Prostate-specific Membrane Antigen-based Radioligand Therapy at the Forefront.
Eur Urol. 2024 Oct 19:S0302-2838(24)02645-9. doi: 10.1016/j.eururo.2024.
PubMed

FENDLER WP, Grunwald V, Herrmann K, Hadaschik BA, et al
Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate Cancer.
Eur Urol. 2024 Oct 19:S0302-2838(24)02648-4. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

GILLESSEN S, Turco F, Davis ID, Efstathiou JA, et al
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).
Eur Urol. 2024 Oct 10:S0302-2838(24)02610-1. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

BAKHT MK, Beltran H
Aiming High: Prostate-specific Membrane Antigen Expression in Treatment-naive Prostate Cancer.
Eur Urol. 2024 Oct 10:S0302-2838(24)02637-X. doi: 10.1016/j.eururo.2024.
PubMed

ONG WL, Loblaw A
Radiotherapy for Unfavorable-risk Prostate Cancer: Biologic Dose Escalation, Fewer Fractions, or Both?
Eur Urol. 2024 Oct 9:S0302-2838(24)02636-8. doi: 10.1016/j.eururo.2024.
PubMed

ROUVIERE O, van Leenders GJLH, Eberli D
Systematic Prostate Biopsy Versus Perilesional Sampling: If It Isn't Broke, Why Fix It?
Eur Urol. 2024;86:295-296.
PubMed Abstract available

BROWN JR, Sonpavde GP, Calaway A, Barata PC, et al
Circulating Tumor DNA To Assess Minimal Residual Disease: Versatile, but How Valuable?
Eur Urol. 2024;86:312-314.
PubMed

CIMADAMORE A, Giannarini G, Crestani A, Lopez-Beltran A, et al
How To Report the Minor Component of a High-grade Pattern in Radical Prostatectomy Specimens: Time To Abandon the "Tertiary" Terminology?
Eur Urol. 2024;86:291-294.
PubMed Abstract available

September 2024

GANDAGLIA G, Barletta F, Briganti A, Montorsi F, et al
Re: Long-term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients with Low-Risk Prostate Cancer.
Eur Urol. 2024 Sep 26:S0302-2838(24)02613-7. doi: 10.1016/j.eururo.2024.
PubMed

CARLSSON SV, Lilja H, Vickers AJ, Bjartell AS, et al
Re: Early Prostate Cancer Deaths Among Men with Higher vs Lower Genetic Risk.
Eur Urol. 2024 Sep 25:S0302-2838(24)02615-0. doi: 10.1016/j.eururo.2024.
PubMed

QI F
Re: Niklas Klumper, Viktor Grunwald, Arndt Hartmann, et al. The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer
Eur Urol. 2024 Sep 25:S0302-2838(24)02612-5. doi: 10.1016/j.eururo.2024.
PubMed

VAN DEN BERGH RCN, Schoots IG, Cornford PA
Standard Repeat Biopsies During Active Surveillance for Prostate Cancer: Are They Necessary in the Magnetic Resonance Imaging Era?
Eur Urol. 2024 Sep 25:S0302-2838(24)02607-1. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

DAI YH, Chen PH, Lee DJ, Andrade G, et al
A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer.
Eur Urol. 2024 Sep 25:S0302-2838(24)02608-3. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

RATHKOPF DE, Roubaud G, Chi KN, Efstathiou E, et al
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial.
Eur Urol. 2024 Sep 23:S0302-2838(24)02594-6. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

UNTERRAINER M, Unterrainer LM, Ilhan H
Re: Robert Seifert, Louise Emmett, Steven P. Rowe, et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol 2023;83:405-12.
Eur Urol. 2024 Sep 23:S0302-2838(24)02617-4. doi: 10.1016/j.eururo.2024.
PubMed

KLUMPER N, Eckstein M
Reply to Feng Qi's Letter to the Editor re: Niklas Klumper, Viktor Grunwald, Arndt Hartmann, et al. The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy
Eur Urol. 2024 Sep 23:S0302-2838(24)02616-2. doi: 10.1016/j.eururo.2024.
PubMed

CHEN DC, Thomson A, Mazzone E, Perera ML, et al
Re: Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer.
Eur Urol. 2024 Sep 20:S0302-2838(24)02513-2. doi: 10.1016/j.eururo.2024.
PubMed

FRANCINI E, Agarwal N, Castro E, Cheng HH, et al
Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review.
Eur Urol. 2024 Sep 20:S0302-2838(24)02599-5. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

BOEVE LMS, Hulshof MCCM, Verhagen PCMS, Twisk JWR, et al
Prostate Cancer-related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial.
Eur Urol. 2024 Sep 19:S0302-2838(24)02593-4. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

AZIZ MK, Molony D, Monlezun D, Holder T, et al
Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment Histories.
Eur Urol. 2024 Sep 18:S0302-2838(24)02569-7. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

WEINER AB, Agrawal R, Wang NK, Sonni I, et al
Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naive Prostate Cancer.
Eur Urol. 2024 Sep 17:S0302-2838(24)02597-1. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

BJERNER J, Bratt O, Aas K, Albertsen PC, et al
Reply to Rongkang Li, Lei Peng, Shaohua Zhang, and Song Wu's Letter to the Editor re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the No
Eur Urol. 2024 Sep 17:S0302-2838(24)02575-2. doi: 10.1016/j.eururo.2024.
PubMed

BRATT O
Prostate Cancer Screening: Setting the Controls on the Mixing Board.
Eur Urol. 2024 Sep 17:S0302-2838(24)02598-3. doi: 10.1016/j.eururo.2024.
PubMed

NIAZI T, Nabid A, Malagon T, Tisseverasinghe S, et al
Hypofractionated Dose Escalation Radiotherapy for High-risk Prostate Cancer: The Survival Analysis of the Prostate Cancer Study 5, a Groupe de Radio-oncologie Genito-urinaire du Quebec-led Phase 3 Trial.
Eur Urol. 2024 Sep 12:S0302-2838(24)02574-0. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

VAN AS N, Yasar B, Griffin C, Patel J, et al
Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial.
Eur Urol. 2024 Sep 11:S0302-2838(24)02568-5. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

LI R, Peng L, Zhang S, Wu S, et al
Re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium. Eur Urol 2024;86:20-6.
Eur Urol. 2024 Sep 5:S0302-2838(24)02564-8. doi: 10.1016/j.eururo.2024.
PubMed

ARMSTRONG AJ, Sartor O, de Bono J, Chi K, et al
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial.
Eur Urol. 2024 Sep 5:S0302-2838(24)02560-0. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

NAIR SS, Muhammad H, Jain P, Xie C, et al
A Novel Artificial Intelligence-powered Tool for Precise Risk Stratification of Prostate Cancer Progression in Patients with Clinical Intermediate Risk.
Eur Urol. 2024 Sep 3:S0302-2838(24)02496-5. doi: 10.1016/j.eururo.2024.
PubMed

KASIVISVANATHAN V, Wai-Shun Chan V, Clement KD, Levis B, et al
VISION: An Individual Patient Data Meta-analysis of Randomised Trials Comparing Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound Guided Biopsy in the Detection of Prostate Cancer.
Eur Urol. 2024 Sep 3:S0302-2838(24)02559-4. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

VYNCKIER P, Annemans L, Roobol M
Reply to Andres Gutierrez, Julio Cesar Boada, and Sebastian Pena's Letter to the Editor re: Pieter Vynckier, Lieven Annemans, Sarah Raes, et al. Systematic Review on the Cost-effectiveness of Prostate Cancer Screening in Europe. Eur Urol. In press. ht
Eur Urol. 2024 Sep 2:S0302-2838(24)02566-1. doi: 10.1016/j.eururo.2024.
PubMed

ACHARD V, Tombal B
All Biochemical Recurrences Are Equal, but Some Are More Equal than Others.
Eur Urol. 2024;86:211-212.
PubMed

August 2024

GUTIERREZ A, Boada JC, Pena S
Re: Pieter Vynckier, Lieven Annemans, Sarah Raes, et al. Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.04.036.
Eur Urol. 2024 Aug 30:S0302-2838(24)02565-X. doi: 10.1016/j.eururo.2024.
PubMed

LEENEN RCA, Venderbos LDF, Helleman J, Gomez Rivas J, et al
Prostate Cancer Early Detection in the European Union and UK.
Eur Urol. 2024 Aug 24:S0302-2838(24)02502-8. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

QI F
Re: Wesley R. Armstrong, Amar U. Kishan, Kiara M. Booker, et al. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter R
Eur Urol. 2024 Aug 21:S0302-2838(24)02557-0. doi: 10.1016/j.eururo.2024.
PubMed

MAY M, Albersen M, Brookman-May S
Re: Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review.
Eur Urol. 2024 Aug 19:S0302-2838(24)02552-1. doi: 10.1016/j.eururo.2024.
PubMed

BRATT O
Re: Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml: Results from the Goteborg-2 Prostate Cancer Screening Trial.
Eur Urol. 2024 Aug 17:S0302-2838(24)02523-5. doi: 10.1016/j.eururo.2024.
PubMed

CHEN DC, Park H, McVey A, Lawrentschuk N, et al
Re: Artificial Intelligence and Radiologists in Prostate Cancer Detection on MRI (PI-CAI): An International, Paired, Non-inferiority, Confirmatory Study.
Eur Urol. 2024 Aug 17:S0302-2838(24)02520-X. doi: 10.1016/j.eururo.2024.
PubMed

GORADIA R, Abdollah F, Sood A
Re: Integrative Multi-Region Molecular Profiling of Primary Prostate Cancer in Men with Synchronous Lymph Node Metastasis.
Eur Urol. 2024 Aug 6:S0302-2838(24)02497-7. doi: 10.1016/j.eururo.2024.
PubMed

KAMRAN SC, Efstathiou JA
Honing Stratification and Treatment for High-risk Prostate Cancer.
Eur Urol. 2024 Aug 6:S0302-2838(24)02489-8. doi: 10.1016/j.eururo.2024.
PubMed

DI LORENZO G, Buonerba C
Re: Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Eur Urol. 2024 Aug 1:S0302-2838(24)02500-4. doi: 10.1016/j.eururo.2024.
PubMed

THOMPSON IM JR
Prostate-specific Antigen Screening in Limbo: How Low Should We Go?
Eur Urol. 2024;86:101-102.
PubMed

MARRA G, Oderda M, Gontero P
Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61-68.
Eur Urol. 2024;86:e36-e37.
PubMed

July 2024

MONTORSI F, Longoni M, Briganti A, Gandaglia G, et al
Re: Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer.
Eur Urol. 2024 Jul 31:S0302-2838(24)02492-8. doi: 10.1016/j.eururo.2024.
PubMed

PARK H, Chen DC, Mazzone E, Grummet J, et al
Re: Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening. The STHLM3-MRI Randomized Clinical Trial.
Eur Urol. 2024 Jul 19:S0302-2838(24)02452-7. doi: 10.1016/j.eururo.2024.
PubMed

MAZZONE E, Perera S, Neti AL, Chen DC, et al
Re: [(177)Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ENZA-p): An Open-label, Multicentre, Randomised, Phase 2 Trial.
Eur Urol. 2024 Jul 19:S0302-2838(24)02450-3. doi: 10.1016/j.eururo.2024.
PubMed

SPRATT DE, Liu VYT, Jia AY, Royce TJ, et al
Meta-analysis of Individual Patient-level Data for a Multimodal Artificial Intelligence Biomarker in High-risk Prostate Cancer: Results from Six NRG/RTOG Phase 3 Randomized Trials.
Eur Urol. 2024 Jul 17:S0302-2838(24)02454-0. doi: 10.1016/j.eururo.2024.
PubMed

HU JC, Schaeffer EM, Vickers AJ
Reply to Ilias Giannakodimos' Letter to the Editor re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREV
Eur Urol. 2024;86:e13.
PubMed

ROSEN GH, Chakiryan NH, Murray KS
Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61-68.
Eur Urol. 2024;86:e14.
PubMed

GIANNAKODIMOS I
Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61-68.
Eur Urol. 2024;86:e12.
PubMed

CHIU PK, Wu X, Gandaglia G
Beyond Statistical Significance: Unveiling the Advantages of Transperineal Versus Transrectal Prostate Biopsies.
Eur Urol. 2024;86:e16-e17.
PubMed

HU JC, Assel M, Allaf ME, Ehdaie B, et al
Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial.
Eur Urol. 2024;86:61-68.
PubMed Abstract available

June 2024

TANEJA SS
Reducing or Increasing Overtreatment? How Do We Measure the Impact of Magnetic Resonance Imaging-targeted Biopsy on Prostate Cancer Mortality?
Eur Urol. 2024 Jun 19:S0302-2838(24)02413-8. doi: 10.1016/j.eururo.2024.
PubMed

COOPERBERG MR
PRECISE v2: An Enhanced Framework To Guide Future Research on the Use of Magnetic Resonance Imaging in Prostate Cancer Active Surveillance.
Eur Urol. 2024 Jun 18:S0302-2838(24)02400-X. doi: 10.1016/j.eururo.2024.
PubMed

SRIVASTAVA A, Lewicki P, Morgan TM
Biomarkers in Prostate Cancer Screening: Sometimes "More is More".
Eur Urol. 2024 Jun 18:S0302-2838(24)02428-X. doi: 10.1016/j.eururo.2024.
PubMed

RAYCHAUDHURI R, DeJong M, Rettig M, Yu EY, et al
Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD Trial.
Eur Urol. 2024 Jun 17:S0302-2838(24)02407-2. doi: 10.1016/j.eururo.2024.
PubMed

MACEK P, Rodriguez-Sanchez L, Cathelineau X
Re: Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of
Eur Urol. 2024 Jun 13:S0302-2838(24)02401-1. doi: 10.1016/j.eururo.2024.
PubMed

ADELEKE S
High-performing, Accessible, and Affordable Imaging in Metastatic Prostate Cancer: Is Whole-body Magnetic Resonance Imaging the Answer?
Eur Urol. 2024 Jun 12:S0302-2838(24)02410-2. doi: 10.1016/j.eururo.2024.
PubMed

May 2024

VICKERS AJ
Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.0
Eur Urol. 2024 May 25:S0302-2838(24)02385-6. doi: 10.1016/j.eururo.2024.
PubMed

ULERI A, Baboudjian M, Diamand R, Ploussard G, et al
Reply to Hein V. Stroomberg, Klaus Brasso, and Andreas Roder's Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer L
Eur Urol. 2024 May 24:S0302-2838(24)02387-X. doi: 10.1016/j.eururo.2024.
PubMed

ULERI A, Baboudjian M, Diamand R, Ploussard G, et al
Reply to Andrew J. Vickers' Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In
Eur Urol. 2024 May 24:S0302-2838(24)02386-8. doi: 10.1016/j.eururo.2024.
PubMed

VYNCKIER P, Annemans L, Raes S, Amrouch C, et al
Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe.
Eur Urol. 2024 May 23:S0302-2838(24)02378-9. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

WEINER AB, Kakani P, Armstrong AJ, Bossi A, et al
Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review.
Eur Urol. 2024 May 22:S0302-2838(24)02375-3. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

RAVI P, Xie W, Buyse M, Halabi S, et al
Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials.
Eur Urol. 2024 May 21:S0302-2838(24)02380-7. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

DALLA VOLTA A, Valcamonico F, Zivi A, Procopio G, et al
Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide.
Eur Urol. 2024 May 20:S0302-2838(24)02347-9. doi: 10.1016/j.eururo.2024.
PubMed

JOSEFSSON A, Mansson M, Kohestani K, Spyratou V, et al
Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GOTEBORG-2 Prostate Cancer Screening Trial.
Eur Urol. 2024 May 20:S0302-2838(24)02379-0. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

BROOKMAN-MAY SD, Buyse M, Freedland SJ, Miladinovic B, et al
Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer.
Eur Urol. 2024 May 17:S0302-2838(24)02348-0. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

PADHANI AR, Lecouvet F, Petralia G, Koh DM, et al
Re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. In press. http
Eur Urol. 2024 May 16:S0302-2838(24)02377-7. doi: 10.1016/j.eururo.2024.
PubMed

GARCIA-RUIZ A, Macarro C, Mateo J, Perez-Lopez R, et al
Reply to Anwar R. Padhani, Frederic LeCouvet, Giuseppe Petralia, and Dow-Mu Koh's Letter to the Editor re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castrati
Eur Urol. 2024 May 16:S0302-2838(24)02376-5. doi: 10.1016/j.eururo.2024.
PubMed

FANKHAUSER CD, Wettstein MS, Wurnschimmel C, van Smeden M, et al
Re: External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.
Eur Urol. 2024 May 15:S0302-2838(24)02340-6. doi: 10.1016/j.eururo.2024.
PubMed

KRILAVICIUTE A, Kaaks R, Seibold P, de Vrieze M, et al
Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial.
Eur Urol. 2024 May 15:S0302-2838(24)02358-3. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

STROOMBERG HV, Brasso K, Roder A
Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.0
Eur Urol. 2024 May 14:S0302-2838(24)02365-0. doi: 10.1016/j.eururo.2024.
PubMed

MERSEBURGER AS, Chowdhury S, Bahl A
Therapy Optimization in the Management of Metastatic Hormone-sensitive Prostate Cancer: Insights from the ARASENS Study.
Eur Urol. 2024 May 14:S0302-2838(24)02364-9. doi: 10.1016/j.eururo.2024.
PubMed

CHIN JL
Re: Incidence and Survival of Secondary Malignancies after External Beam Radiotherapy for Prostate Cancer in the SEER Database.
Eur Urol. 2024 May 13:S0302-2838(24)02344-3. doi: 10.1016/j.eururo.2024.
PubMed

KLUMPER N, Grunwald V, Hartmann A, Holzel M, et al
The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer.
Eur Urol. 2024 May 13:S0302-2838(24)02350-9. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

OKOLI S, Okoli O, Ding H, Adeleke S, et al
Re: Actinium-225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer (WARMTH Act): A Multicentre, Retrospective Study.
Eur Urol. 2024 May 11:S0302-2838(24)02352-2. doi: 10.1016/j.eururo.2024.
PubMed

LIGHT A, Mayor N, Cullen E, Kirkham A, et al
The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations.
Eur Urol. 2024;85:466-482.
PubMed Abstract available

ANAND M, Jain B, Aggarwal S
Re: Rudolf A. Werner, Philipp E. Hartrampf, Wolfgang P. Fendler, et al. Prostate-specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 2023;84:491-502.
Eur Urol. 2024;85:e145.
PubMed

HARTRAMPF PE, Rowe SP, Pomper MG, Higuchi T, et al
Reply to Madhur Anand, Bela Jain, and Swati Aggarwal's Letter to the Editor re: Rudolf A. Werner, Philipp E. Hartrampf, Wolfgang P. Fendler, et al. Prostate-Specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 2023;84:491-502.
Eur Urol. 2024;85:e146-e147.
PubMed

April 2024

TILKI D, van den Bergh RCN, Briers E, Van den Broeck T, et al
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
Eur Urol. 2024 Apr 29:S0302-2838(24)02306-6. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

OST P, Siva S, Zilli T
OLIGOPELVIS and the "All You Can Eat" Strategy for Oligorecurrent Nodal Prostate Cancer: Are We Already Full?
Eur Urol. 2024 Apr 27:S0302-2838(24)02307-8. doi: 10.1016/j.eururo.2024.
PubMed

HU JC, Vickers AJ, Schaeffer EM
Reply to Peter Ka-Fung Chiu, Xiaobo Wu, Giorgio Gandaglia, European Association of Urology Young Academic Urologists Prostate Cancer Working Party. Beyond Statistical Significance: Unveiling the Advantages of Transperineal Versus Transrectal Prostate
Eur Urol. 2024 Apr 26:S0302-2838(24)02314-5. doi: 10.1016/j.eururo.2024.
PubMed

CHAKRABARTI D, Parker CC
Metastatic Hormone-sensitive Prostate Cancer: Patient Selection for Prostate Radiotherapy.
Eur Urol. 2024 Apr 26:S0302-2838(24)02308-X. doi: 10.1016/j.eururo.2024.
PubMed

SAAD F, Hussain MHA, Tombal B, Fizazi K, et al
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of
Eur Urol. 2024 Apr 20:S0302-2838(24)02264-4. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

HINDIE E, Champion C, Morgat C
Re: Renu S. Eapen, James P. Buteau, Price Jackson, et al. Administering [(177)Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. Eur Urol. In press.
Eur Urol. 2024 Apr 20:S0302-2838(24)02310-8. doi: 10.1016/j.eururo.2024.
PubMed

CARDONA ORTEGON JD, Campana Perilla LA, Olarte Bermudez LM
Re: Matthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial. Eur Urol 2024;85:105-11
Eur Urol. 2024 Apr 20:S0302-2838(24)02315-7. doi: 10.1016/j.eururo.2024.
PubMed

CORNFORD P, van den Bergh RCN, Briers E, Van den Broeck T, et al
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.
Eur Urol. 2024 Apr 12:S0302-2838(24)02254-1. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

GRABBERT M, Liakos N, Gratzke C
Re: Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.
Eur Urol. 2024 Apr 11:S0302-2838(24)02258-9. doi: 10.1016/j.eururo.2024.
PubMed

RUSH HL, Gilbert DC, Langley RE
Re: Bertrand Tombal, Sean Collins, Alicia K. Morgans, et al. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Eur Urol 2023;84:579-87.
Eur Urol. 2024 Apr 6:S0302-2838(24)02251-6. doi: 10.1016/j.eururo.2024.
PubMed

ROY S, Fervaha G, Spratt DE, Sun Y, et al
Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
Eur Urol. 2024 Apr 2:S0302-2838(24)02239-5. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

ROY S, Saad F, Malone S, Agarwal N, et al
Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study.
Eur Urol. 2024;85:398-400.
PubMed

O'CALLAGHAN M, Bulamu N, Gormly K, Jay A, et al
Re: Prevalence of MRI Lesions in Men Responding to a GP-led Invitation for a Prostate Health Check: A Prospective Cohort Study.
Eur Urol. 2024;85:395.
PubMed

March 2024

ENGLMAN C, Maffei D, Allen C, Kirkham A, et al
PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer.
Eur Urol. 2024 Mar 30:S0302-2838(24)02232-2. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

LOGOTHETIS CJ, Hahn AW
Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo's Letter to the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024
Eur Urol. 2024 Mar 26:S0302-2838(24)02240-1. doi: 10.1016/j.eururo.2024.
PubMed

WASSERSUG RJ, Schellhammer PF, Wibowo E
Re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3-7.
Eur Urol. 2024 Mar 26:S0302-2838(24)02233-4. doi: 10.1016/j.eururo.2024.
PubMed

WINDISCH O, Valerio M
Re: Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of Localised Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-year Experience.
Eur Urol. 2024 Mar 26:S0302-2838(24)02208-5. doi: 10.1016/j.eururo.2024.
PubMed

DE MEERLEER G, Joniau S, Benijts J, Rans K, et al
Oligometastatic Recurrent Prostate Cancer: Whether To Intensify Treatment or Not.
Eur Urol. 2024 Mar 22:S0302-2838(24)02238-3. doi: 10.1016/j.eururo.2024.
PubMed

BURGER M
Re: First-in-human Evaluation of a Prostate-specific Membrane Antigen-targeted Near-infrared Fluorescent Small Molecule for Fluorescence-based Identification of Prostate Cancer in Patients with High-risk Prostate Cancer Undergoing Robotic-assisted Pro
Eur Urol. 2024 Mar 22:S0302-2838(24)02205-X. doi: 10.1016/j.eururo.2024.
PubMed

NIKITAS J, Rettig M, Shen J, Reiter R, et al
Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.
Eur Urol. 2024 Mar 16:S0302-2838(24)00058-7. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

BABOUDJIAN M, Diamand R, Uleri A, Beauval JB, et al
Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment?
Eur Urol. 2024 Mar 16:S0302-2838(24)00071-X. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

CUSSENOT O, Chambaz A, Hamdy FC
Re: Annika Herlemann, Janet E. Cowan, Samuel L. Washington 3rd, et al. Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer. Eur
Eur Urol. 2024 Mar 15:S0302-2838(24)02139-0. doi: 10.1016/j.eururo.2024.
PubMed

GARCIA-RUIZ A, Macarro C, Zacchi F, Morales-Barrera R, et al
Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial.
Eur Urol. 2024 Mar 14:S0302-2838(24)02133-X. doi: 10.1016/j.eururo.2024.
PubMed

MOLLER F, Mansson M, Wallstrom J, Hellstrom M, et al
Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml: Results from the Goteborg-2 Prostate Cancer Screening Trial.
Eur Urol. 2024 Mar 14:S0302-2838(24)00052-6. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

WEBER M, Fendler WP, Ravi Kumar AS, Calais J, et al
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study.
Eur Urol. 2024 Mar 14:S0302-2838(24)00054-X. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

VAUGIER L, Morvan C, Pasquier D, Buthaud X, et al
Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07).
Eur Urol. 2024 Mar 14:S0302-2838(24)02131-6. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

NICKOLS NG, Tsai S, Kane N, Tran S, et al
Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer.
Eur Urol. 2024 Mar 14:S0302-2838(24)00079-4. doi: 10.1016/j.eururo.2024.
PubMed

MONTIRONI R, Cimadamore A, Giannarini G, Crestani A, et al
Re: Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population.
Eur Urol. 2024 Mar 14:S0302-2838(24)02141-9. doi: 10.1016/j.eururo.2024.
PubMed

FODOR A, Brombin C, Chiti A, Di Muzio N, et al
Re: Marcin Miszczyk, Pawel Rajawa, Takafumi Yanagisawa, et al. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies. Eur Urol. In press. https://doi.org/1
Eur Urol. 2024 Mar 12:S0302-2838(24)02140-7. doi: 10.1016/j.eururo.2024.
PubMed

SARTOR O
Prostate-specific Membrane Antigen-targeted Isotope Therapy: Inherent Challenges Owing to Heterogeneity and Clonal Evolution.
Eur Urol. 2024;85:205-206.
PubMed

PILATZ A, MacLennan S, van den Bergh RCN, Veeratterapillay R, et al
Reply to Badar M. Mian. Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise. Eur Urol. 2024;85:99-100.
Eur Urol. 2024;85:313-314.
PubMed

February 2024

GOLIJANIN B, Mega A, Golijanin D
Re: Ivo I. de Vos II, Sebastiaan Remmers, Renee Hogenhout, Monique J. Roobol, ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Scr
Eur Urol. 2024 Feb 29:S0302-2838(24)00081-2. doi: 10.1016/j.eururo.2024.
PubMed

POPE B, Park G, Lau E, Belic J, et al
Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer.
Eur Urol. 2024 Feb 19:S0302-2838(24)00003-4. doi: 10.1016/j.eururo.2024.
PubMed

FENG D, Wang J, Wu R, Li D, et al
Re: Immune System and Intestinal Microbiota Determine Efficacy of Androgen Deprivation Therapy Against Prostate Cancer.
Eur Urol. 2024 Feb 17:S0302-2838(24)00069-1. doi: 10.1016/j.eururo.2024.
PubMed

DE VOS II, Remmers S, Roobol MJ
Reply to Borivoj Golijanin, Anthony Mega, and Dragan Golijanin's Letter to the Editor re: Ivo I. de Vos, Sebastiaan Remmers, Renee Hogenhout, Monique J. Roobol, ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After Discontinui
Eur Urol. 2024 Feb 17:S0302-2838(24)00057-5. doi: 10.1016/j.eururo.2024.
PubMed

DEIVASIGAMANI S, Kotamarti S, Gupta RT, Polascik TJ, et al
Re: Low Cancer Yield in PI-RADS 3 Upgraded to 4 by Dynamic Contrast-enhanced MRI: Is It Time To Reconsider Scoring Categorization?
Eur Urol. 2024;85:180-181.
PubMed

PREISSER F, Abrams-Pompe RS, Stelwagen PJ, Bohmer D, et al
European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study.
Eur Urol. 2024;85:164-170.
PubMed Abstract available

MIAN BM
Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise.
Eur Urol. 2024;85:99-100.
PubMed Abstract available

January 2024

ARMSTRONG WR, Kishan AU, Booker KM, Grogan TR, et al
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774).
Eur Urol. 2024 Jan 29:S0302-2838(24)00013-7. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

VICKERS AJ, Assel M, Cooperberg MR, Fine SW, et al
Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate Cancer.
Eur Urol. 2024 Jan 25:S0302-2838(24)00007-1. doi: 10.1016/j.eururo.2024.
PubMed Abstract available

CHI KN, Armstrong AJ, Krause BJ, Herrmann K, et al
Safety Analyses of the Phase 3 VISION Trial of [(177)Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.
Eur Urol. 2024 Jan 6:S0302-2838(23)03297-9. doi: 10.1016/j.eururo.2023.
PubMed Abstract available

December 2023

LIU M, Chen P, Li T
Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phas
Eur Urol. 2023 Dec 21:S0302-2838(23)03293-1. doi: 10.1016/j.eururo.2023.
PubMed

HUANG TB, Ding XF
Re: Matthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial, Eur Urol. In press. htt
Eur Urol. 2023 Dec 16:S0302-2838(23)03294-3. doi: 10.1016/j.eururo.2023.
PubMed

ALBERS P, van Poppel H
Prostate Cancer Screening at its Best: The Swedish Organized Prostate Cancer Testing Program.
Eur Urol. 2023 Dec 15:S0302-2838(23)03290-6. doi: 10.1016/j.eururo.2023.
PubMed

CORPETTI M, Muller C, Beltran H, de Bono J, et al
Prostate-Specific Membrane Antigen-Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes.
Eur Urol. 2023 Dec 15:S0302-2838(23)03278-5. doi: 10.1016/j.eururo.2023.
PubMed Abstract available

FERNANDEZ-ZAPATA WF, Gandur Quiroga MN, Cardona Maya WD
Re: Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Eur Urol. 2023 Dec 11:S0302-2838(23)03283-9. doi: 10.1016/j.eururo.2023.
PubMed

RAGGI D, Cigliola A, Mercinelli C, Patane D, et al
Re: Which Patients with Metastatic Hormone-sensitive Prostate Cancer Benefit from Docetaxel: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Trials.
Eur Urol. 2023 Dec 11:S0302-2838(23)03260-8. doi: 10.1016/j.eururo.2023.
PubMed

KAPLAN-MARANS E, Zhang TR, Hu JC
Reply to Fabian Falkenbach, Francesco Sanguedolce, and Lars Budaus's Letter to the Editor re: Elie Kaplan-Marans, Tenny R. Zhang, Jim C. Hu. Differing Recommendations on Prostate Biopsy Approach to Minimize Infections: An Examination of the European A
Eur Urol. 2023;84:e151.
PubMed

CAPOGROSSO P, Deho F, Salonia A, Briganti A, et al
Re: Jean-Nicolas Cornu, Paul Zantek, Glyn Burtt, et al. Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis. Eur Urol 2023;83:534-47.
Eur Urol. 2023;84:e146.
PubMed

DJAILEB L, Armstrong WR, Thompson D, Gafita A, et al
Presurgical (68)Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial.
Eur Urol. 2023;84:588-596.
PubMed Abstract available

SAAD F, Del Rosario P, Clarke NW
Reply to Lin Ding, Bin Yang, and Xudong Yao's Letter to the Editor re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespe
Eur Urol. 2023 Dec 1:S0302-2838(23)03274-8. doi: 10.1016/j.eururo.2023.
PubMed

BRATT O, Godtman RA, Jiborn T, Wallstrom J, et al
Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men.
Eur Urol. 2023 Dec 1:S0302-2838(23)03272-4. doi: 10.1016/j.eururo.2023.
PubMed Abstract available

FALKENBACH F, Sanguedolce F, Budaus L
Re: Elie Kaplan-Marans, Tenny R. Zhang, Jim C. Hu. Differing Recommendations on Prostate Biopsy Approach to Minimize Infections: An Examination of the European Association of Urology and American Urological Association Guidelines. Eur Urol. 2023;84:44
Eur Urol. 2023;84:e149-e150.
PubMed

November 2023

GIESEN A, Devlies W, Claessens F, Joniau S, et al
Re: Abiraterone and Olaparib for Metastatic Castration-resistant Prostate Cancer.
Eur Urol. 2023 Nov 27:S0302-2838(23)03273-6. doi: 10.1016/j.eururo.2023.
PubMed

DING L, Yang B, Yao X
Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phas
Eur Urol. 2023 Nov 23:S0302-2838(23)03226-8. doi: 10.1016/j.eururo.2023.
PubMed

MUN CHOW K, Zheng So W, Jie Lee H, Lee A, et al
Corrigendum to "Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic R
Eur Urol. 2023 Nov 14:S0302-2838(23)03213-X. doi: 10.1016/j.eururo.2023.
PubMed

MOORE CM, Albertsen P
When Is It Too Early To Start Prostate Cancer Screening? Reflections on the PROBASE Study Using Magnetic Resonance Imaging for Men Aged 45 Yr with Elevated Prostate-specific Antigen.
Eur Urol. 2023 Nov 13:S0302-2838(23)03212-8. doi: 10.1016/j.eururo.2023.
PubMed

HAMDY FC, Donovan JL
Reply to Greg Shaw, John D. Kelly, and Monique J. Roobol's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:
Eur Urol. 2023 Nov 8:S0302-2838(23)03218-9. doi: 10.1016/j.eururo.2023.
PubMed

MISZCZYK M, Rajwa P, Yanagisawa T, Nowicka Z, et al
The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies.
Eur Urol. 2023 Nov 7:S0302-2838(23)03209-8. doi: 10.1016/j.eururo.2023.
PubMed Abstract available

TRUJILLO CG, Pena Rodriguez S, Diaz Ritter C
Re: Jean-Nicolas Cornu, Paul Zantek, Glyn Burtt, et al. Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis. Eur Urol. 2023;83:534-47.
Eur Urol. 2023;84:e116.
PubMed

FENG T, Ren M, Zhou Z
Re: Peter Fletcher, Marta De Santis, Simona Ippoliti, et al. Vector Prostate Biopsy: A Novel Magnetic Resonance Imaging/Ultrasound Image Fusion Transperineal Biopsy Technique Using Electromagnetic Needle Tracking Under Local Anaesthesia. Eur Urol 2023
Eur Urol. 2023;84:e114.
PubMed

LINDER S, Severson TM, van der Mijn KJC, Nevedomskaya E, et al
Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.
Eur Urol. 2023;84:455-460.
PubMed Abstract available

WERNER RA, Hartrampf PE, Fendler WP, Serfling SE, et al
Prostate-specific Membrane Antigen Reporting and Data System Version 2.0.
Eur Urol. 2023;84:491-502.
PubMed Abstract available

October 2023

DE VOS II, Remmers S, Hogenhout R, Roobol MJ, et al
Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.
Eur Urol. 2023 Oct 31:S0302-2838(23)03207-4. doi: 10.1016/j.eururo.2023.
PubMed Abstract available

SHAW G, Kelly JD, Roobol MJ
Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-58.
Eur Urol. 2023 Oct 26:S0302-2838(23)03170-6. doi: 10.1016/j.eururo.2023.
PubMed

EAPEN RS, Buteau JP, Jackson P, Mitchell C, et al
Administering [(177)Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study.
Eur Urol. 2023 Oct 25:S0302-2838(23)03087-7. doi: 10.1016/j.eururo.2023.
PubMed Abstract available

SHARMA AD, Good DW, Alan McNeill S
Re: Patient-reported Outcomes 12 Years after Localized Prostate Cancer Treatment.
Eur Urol. 2023 Oct 19:S0302-2838(23)03157-3. doi: 10.1016/j.eururo.2023.
PubMed

BOSCHHEIDGEN M, Albers P, Schlemmer HP, Hellms S, et al
Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.
Eur Urol. 2023 Oct 18:S0302-2838(23)03158-5. doi: 10.1016/j.eururo.2023.
PubMed Abstract available

HERLEMANN A, Cowan JE, Washington SL 3rd, Wong AC, et al
Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer.
Eur Urol. 2023 Oct 17:S0302-2838(23)03155-X. doi: 10.1016/j.eururo.2023.
PubMed Abstract available

SORCE G, Mottrie A
Re: Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Study that Challenges the Dogma.
Eur Urol. 2023 Oct 14:S0302-2838(23)03159-7. doi: 10.1016/j.eururo.2023.
PubMed

GANDAGLIA G, Barletta F, Briganti A, Montorsi F, et al
Re: Laura Bukavina, Amy N. Luckenbaugh, Michael S. Hofman, et al. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. Eur Urol 2
Eur Urol. 2023 Oct 11:S0302-2838(23)03140-8. doi: 10.1016/j.eururo.2023.
PubMed

KRAFFT U, Hadaschik BA, Luckerath K, Herrmann K, et al
A New Chapter in Neoadjuvant Therapy for High-risk Prostate Cancer?
Eur Urol. 2023 Oct 11:S0302-2838(23)03149-4. doi: 10.1016/j.eururo.2023.
PubMed

TOMBAL B, Collins S, Morgans AK, Hunsche E, et al
Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Eur Urol. 2023 Oct 11:S0302-2838(23)03099-3. doi: 10.1016/j.eururo.2023.
PubMed Abstract available

JUNG J, Kim JH
Re: Casey Crump, Par Stattin, James D. Brooks, et al. Long-term Risks of Depression and Suicide Among Men with Prostate Cancer: A National Cohort Study. Eur Urol 2023;84:263-72.
Eur Urol. 2023 Oct 11:S0302-2838(23)03154-8. doi: 10.1016/j.eururo.2023.
PubMed

HICKS RJ
The Pythia Speaks on Prostate Cancer Diagnosis and Treatment.
Eur Urol. 2023 Oct 11:S0302-2838(23)03148-2. doi: 10.1016/j.eururo.2023.
PubMed

KISHAN AU, Valle LF, Marks LS
Bullseye or Tip of the Iceberg: Magnetic Resonance Imaging-visible Disease in Radiorecurrent Prostate Cancer.
Eur Urol. 2023 Oct 5:S0302-2838(23)03145-7. doi: 10.1016/j.eururo.2023.
PubMed

COLE AP, Gupta N, Loeb S
The Plant-based Prescription: How Dietary Change Can Improve Both Urological and Planetary Health.
Eur Urol. 2023;84:357-358.
PubMed Abstract available

HEIJNSDIJK EAM, de Koning HJ
Wise Prostate-specific Antigen Testing Means a Limited, Risk-adjusted, and Personal Approach.
Eur Urol. 2023;84:359-360.
PubMed

September 2023

LIGHT A, Kanthabalan A, Otieno M, Pavlou M, et al
The Role of Multiparametric MRI and MRI-targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial.
Eur Urol. 2023 Sep 29:S0302-2838(23)03089-0. doi: 10.1016/j.eururo.2023.
PubMed Abstract available

LAMBERT E, Roupret M
Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer.
Eur Urol. 2023 Sep 27:S0302-2838(23)03137-8. doi: 10.1016/j.eururo.2023.
PubMed

BEATRICI E, Labban M, Stone BV, Filipas DK, et al
Uncovering the Changing Treatment Landscape for Low-risk Prostate Cancer in the USA from 2010 to 2020: Insights from the National Cancer Data Base.
Eur Urol. 2023 Sep 25:S0302-2838(23)03088-9. doi: 10.1016/j.eururo.2023.
PubMed Abstract available

PONTES-SILVA A
Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023
Eur Urol. 2023 Sep 25:S0302-2838(23)03094-4. doi: 10.1016/j.eururo.2023.
PubMed

ILIE G, Rutledge RDH
Reply to Andre Pontes-Silva's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Tr
Eur Urol. 2023 Sep 22:S0302-2838(23)03091-9. doi: 10.1016/j.eururo.2023.
PubMed

MAY M, Wolff I, Brookman-May SD
Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023
Eur Urol. 2023 Sep 22:S0302-2838(23)03095-6. doi: 10.1016/j.eururo.2023.
PubMed

KLOTZ L
Re: MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After Prostatectomy.
Eur Urol. 2023 Sep 22:S0302-2838(23)03080-4. doi: 10.1016/j.eururo.2023.
PubMed

OPREA-LAGER DE, MacLennan S, Bjartell A, Briganti A, et al
European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer.
Eur Urol. 2023 Sep 22:S0302-2838(23)03092-0. doi: 10.1016/j.eururo.2023.
PubMed Abstract available

ILIE G, Rutledge RDH
Reply to Matthias May, Ingmar Wolff, and Sabine D. Brookman-May's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Un
Eur Urol. 2023 Sep 22:S0302-2838(23)03093-2. doi: 10.1016/j.eururo.2023.
PubMed

VAN POPPEL H, Roobol MJ, Chandran A
Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U.
Eur Urol. 2023 Sep 11:S0302-2838(23)03023-3. doi: 10.1016/j.eururo.2023.
PubMed Abstract available

MICHEL MC
Re: Genetically Adjusted PSA Levels for Prostate Cancer Screening.
Eur Urol. 2023 Sep 9:S0302-2838(23)03081-6. doi: 10.1016/j.eururo.2023.
PubMed

ROCCO B, Sighinolfi MC
Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023; 388:1547-58.
Eur Urol. 2023 Sep 6:S0302-2838(23)03069-5. doi: 10.1016/j.eururo.2023.
PubMed

August 2023

PAPACHRISTODOULOU A, Heidegger I, Virk RK, Di Bernardo M, et al
Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression.
Eur Urol. 2023 Aug 31:S0302-2838(23)03016-6. doi: 10.1016/j.eururo.2023.
PubMed Abstract available

HAMDY FC, Donovan JL
Reply to Bernardo Rocco and Maria Chiara Sighinolfi's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-
Eur Urol. 2023 Aug 31:S0302-2838(23)03070-1. doi: 10.1016/j.eururo.2023.
PubMed

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum